1	The	the	DT	_	2	det	_
2	boss	boss	NN	_	5	nsubj	5:A0
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	3	pobj	_
5	says	say	VBZ	pb=say.01	0	root	_
6	there	there	EX	_	9	expl	_
7	will	will	MD	_	9	aux	9:AM-MOD
8	not	not	RB	_	9	neg	9:AM-NEG
9	be	be	VB	pb=be.02	5	ccomp	5:A1=PPT
10	a	a	DT	_	11	det	_
11	deal	deal	NN	_	9	attr	9:A1=PPT
12	or	or	CC	_	11	cc	_
13	takeover	takeover	NN	_	14	nn	_
14	deadline	deadline	NN	_	15	nn	_
15	extension	extension	NN	_	11	conj	_
16	in	in	IN	_	15	prep	_
17	its	its	PRP$	_	19	poss	_
18	latest	late	JJS	_	19	amod	_
19	tussle	tussle	NN	p2=VBP	16	pobj	_
20	with	with	IN	_	19	prep	_
21	drug	drug	NN	_	22	nn	_
22	rival	rival	NN	p2=JJ	20	pobj	_
23	Pfizer	pfizer	NNP	p2=NN	22	appos	_
24	.	.	.	_	5	punct	_

1	Video	video	NN	p2=NNP	16	dep	_
2	:	:	:	_	1	punct	_
3	AstraZeneca	astrazeneca	NNP	_	7	poss	_
4	'	'	POS	p2=''	3	possessive	_
5	Sets	set	NNPS	p2=NNP	7	nn	_
6	Takeover	takeover	NNP	_	7	nn	_
7	Price	price	NNP	_	9	poss	_
8	'	'	POS	p2=''	7	possessive	_
9	Video	video	NNP	p2=NN	1	appos	_
10	:	:	:	p2=HYPH	9	punct	_
11	AstraZeneca	astrazeneca	NNP	p2=JJ	12	nn	_
12	chairman	chairman	NN	_	9	appos	_
13	:	:	:	_	9	punct	_
14	'	'	''	p2=``	9	punct	_
15	Bid	bid	NNP	p2=JJ	16	nsubj	16:A0=PAG
16	creates	create	VBZ	pb=create.01	24	ccomp	_
17	considerable	considerable	JJ	_	18	amod	_
18	risk	risk	NN	_	16	dobj	16:A1=PPT
19	'	'	''	p2=``	18	punct	_
20	The	the	DT	_	21	det	_
21	boss	boss	NN	_	18	appos	_
22	of	of	IN	_	21	prep	_
23	AstraZeneca	astrazeneca	NNP	_	22	pobj	_
24	said	say	VBD	pb=say.01	0	root	_
25	there	there	EX	_	26	expl	_
26	was	be	VBD	pb=be.02	24	ccomp	24:A1=PPT
27	no	no	DT	_	28	det	_
28	prospect	prospect	NN	_	26	attr	26:A1=PPT
29	of	of	IN	_	28	prep	_
30	a	a	DT	_	31	det	_
31	deal	deal	NN	_	29	pobj	_
32	with	with	IN	_	31	prep	_
33	US	us	NNP	_	35	nn	_
34	drug	drug	NN	_	35	nn	_
35	giant	giant	NN	p2=JJ	36	nn	_
36	Pfizer	pfizer	NNP	p2=NN	32	pobj	_
37	before	before	IN	_	26	prep	_
38	a	a	DT	_	40	det	_
39	set	set	NN	p2=VBN	40	nn	_
40	deadline	deadline	NN	_	37	pobj	_
41	of	of	IN	_	40	prep	_
42	May	may	NNP	_	41	pobj	_
43	26	0	CD	_	42	num	_
44	.	.	.	_	24	punct	_

1	Chairman	chairman	NNP	p2=NN	3	nn	_
2	Leif	leif	NNP	_	3	nn	_
3	Johansson	johansson	NNP	_	5	nsubj	5:A0
4	also	also	RB	_	5	advmod	5:AM-DIS
5	said	say	VBD	pb=say.01	0	root	_
6	there	there	EX	_	7	expl	_
7	was	be	VBD	pb=be.02	5	ccomp	5:A1=PPT
8	no	no	DT	_	9	det	_
9	likelihood	likelihood	NN	_	7	attr	7:A1=PPT
10	of	of	IN	_	9	prep	_
11	a	a	DT	_	13	det	_
12	deadline	deadline	NN	_	13	nn	_
13	extension	extension	NN	_	10	pobj	_
14	,	,	,	_	17	punct	_
15	under	under	IN	_	9	prep	_
16	rules	rule	NNS	_	15	pobj	17:A1=PPT
17	laid	lay	VBN	p2=VBD|pb=lay.01	16	partmod	_
18	down	down	RP	_	17	prt	17:AM-ADV
19	by	by	IN	_	17	agent	17:A0=PAG
20	the	the	DT	_	22	det	_
21	Takeover	takeover	NN	p2=NNP	22	nn	_
22	Panel	panel	NNP	p2=NN	19	pobj	_
23	.	.	.	_	5	punct	_

1	Mr	mr	NNP	_	2	nn	_
2	Johansson	johansson	NNP	_	3	nsubj	3:A0
3	said	say	VBD	pb=say.01	0	root	_
4	that	that	IN	_	6	complm	_
5	it	it	PRP	_	6	nsubj	6:A1=PPT
6	was	be	VBD	pb=be.01	3	ccomp	3:A1=PPT
7	Pfizer	pfizer	NNP	_	6	attr	13:A0=PAG;6:A2=PRD
8	,	,	,	_	7	punct	_
9	not	not	RB	_	7	neg	_
10	AstraZeneca	astrazeneca	NNP	_	7	appos	_
11	,	,	,	_	7	punct	_
12	that	that	WDT	p2=DT	13	nsubj	13:R-A0
13	called	call	VBD	pb=call.03	7	rcmod	_
14	an	an	DT	_	15	det	_
15	end	end	NN	_	13	dobj	13:A1=PPT
16	to	to	IN	_	15	prep	_
17	discussions	discussion	NNS	_	16	pobj	_
18	on	on	IN	_	17	prep	_
19	Sunday	sunday	NNP	_	20	nn	_
20	afternoon	afternoon	NN	_	18	pobj	_
21	about	about	IN	_	17	prep	_
22	a	a	DT	_	24	det	_
23	potential	potential	JJ	_	24	amod	_
24	takeover	takeover	NN	_	21	pobj	_
25	to	to	TO	_	26	aux	_
26	create	create	VB	pb=create.01	13	advcl	13:AM-PRP
27	the	the	DT	_	28	det	_
28	world	world	NN	_	32	poss	_
29	's	's	POS	_	28	possessive	_
30	largest	large	JJS	_	32	amod	_
31	drug	drug	NN	_	32	nn	_
32	maker	maker	NN	_	26	dobj	26:A1=PPT
33	.	.	.	_	3	punct	_

1	Early	early	RB	_	5	advmod	5:AM-TMP
2	Monday	monday	NNP	_	3	nn	_
3	morning	morning	NN	_	4	nn	_
4	AstraZeneca	astrazeneca	NNP	_	5	nsubj	5:A0=PAG
5	announced	announce	VBD	pb=announce.01	0	root	_
6	a	a	DT	_	7	det	_
7	rejection	rejection	NN	_	5	dobj	5:A1=PPT
8	of	of	IN	_	7	prep	_
9	Pfizer	pfizer	NNP	_	16	poss	_
10	's	's	POS	_	9	possessive	_
11	"	"	``	_	13	punct	_
12	final	final	JJ	_	13	amod	_
13	offer	offer	NN	_	16	nn	_
14	"	"	''	_	13	punct	_
15	takeover	takeover	NN	_	16	nn	_
16	bid	bid	NN	_	8	pobj	19:A0
17	,	,	,	_	16	punct	_
18	which	which	WDT	_	19	nsubj	19:R-A0
19	valued	value	VBD	pb=value.01	16	rcmod	_
20	the	the	DT	_	21	det	_
21	company	company	NN	_	19	dobj	19:A1
22	at	at	IN	_	19	prep	19:A2=PRD
23	£69.3bn	£69.3bn	NNP	p2=CD	22	pobj	_
24	(	(	-LRB-	_	23	punct	_
25	$	$	$	p2=``	26	nmod	_
26	119bn	0bn	CD	p2=NNP	23	appos	_
27	)	)	-RRB-	_	23	punct	_
28	.	.	.	_	5	punct	_

1	The	the	DT	_	4	det	_
2	British	british	JJ	_	4	amod	_
3	drug	drug	NN	_	4	nn	_
4	firm	firm	NN	_	5	nsubj	5:A0
5	said	say	VBD	pb=say.01	0	root	_
6	the	the	DT	_	7	det	_
7	offer	offer	NN	_	12	nsubj	12:A1=PPT
8	of	of	IN	_	7	prep	_
9	£55	£0	CD	p2=PDT	8	pobj	_
10	a	a	DT	_	11	det	_
11	share	share	NN	_	9	npadvmod	_
12	falls	fall	VBZ	pb=fall.01	5	ccomp	5:A1=PPT
13	short	short	JJ	_	12	advmod	12:A2=EXT
14	of	of	IN	_	13	prep	_
15	its	its	PRP$	_	16	poss	_
16	value	value	NN	_	14	pobj	_
17	as	as	IN	_	16	prep	_
18	an	an	DT	_	20	det	_
19	independent	independent	JJ	_	20	amod	_
20	company	company	NN	_	17	pobj	_
21	and	and	CC	_	12	cc	_
22	that	that	IN	p2=WDT	28	mark	_
23	its	its	PRP$	_	26	poss	_
24	larger	large	JJR	_	26	amod	_
25	US	us	NNP	_	26	nn	_
26	rival	rival	NN	p2=RB	28	nsubj	31:A0=PAG;28:A1=PAG
27	had	have	VBD	_	28	aux	_
28	failed	fail	VBN	pb=fail.01	17	conj	_
29	to	to	TO	_	31	aux	_
30	"	"	``	_	31	punct	_
31	make	make	VB	pb=make.05	28	xcomp	28:A2=PPT
32	a	a	DT	_	35	det	_
33	compelling	compelling	JJ	_	35	amod	_
34	strategic	strategic	JJ	_	35	amod	_
35	business	business	NN	_	38	nn	_
36	or	or	CC	_	35	cc	_
37	value	value	NN	_	35	conj	_
38	case	case	NN	_	31	dobj	31:A1=PPT
39	"	"	''	_	31	punct	_
40	.	.	.	_	5	punct	_

1	It	it	PRP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	the	the	DT	_	5	det	_
4	Pfizer	pfizer	NNP	_	5	nn	_
5	proposals	proposal	NNS	_	7	nsubj	7:A0=PAG
6	would	would	MD	_	7	aux	7:AM-MOD
7	bring	bring	VB	pb=bring.01	2	ccomp	2:A1=PPT
8	"	"	``	_	7	punct	_
9	uncertainty	uncertainty	NN	_	7	dobj	7:A1=PPT
10	and	and	CC	_	9	cc	_
11	risks	risk	NNS	p2=VBZ	9	conj	_
12	"	"	''	p2=``	7	punct	_
13	for	for	IN	_	7	prep	7:A2=GOL
14	AstraZeneca	astrazeneca	NNP	p2=JJ	15	nn	_
15	shareholders	shareholder	NNS	_	13	pobj	_
16	.	.	.	_	2	punct	_

1	Mr	mr	NNP	p2=NN	2	nn	_
2	Johansson	johansson	NNP	_	3	nsubj	3:A0=PAG
3	told	tell	VBD	pb=tell.01	0	root	_
4	Sky	sky	NNP	_	5	nn	_
5	News	news	NNP	p2=NN	3	dobj	3:A1=PPT
6	:	:	:	_	3	punct	_
7	"	"	``	_	3	punct	_
8	We	we	PRP	_	9	nsubj	9:A0=PAG
9	rejected	reject	VBD	pb=reject.01	3	ccomp	_
10	the	the	DT	_	11	det	_
11	bid	bid	NN	_	9	dobj	9:A1=PPT
12	on	on	IN	_	11	prep	_
13	three	#crd#	CD	_	14	num	_
14	grounds	ground	NNS	_	12	pobj	_
15	.	.	.	_	3	punct	_

1	First	#ord#	RB	_	4	advmod	4:AM-DIS
2	,	,	,	_	4	punct	_
3	we	we	PRP	_	4	nsubj	4:A0
4	think	think	VBP	pb=think.01	0	root	_
5	it	it	PRP	_	6	nsubj	6:A0=PAG
6	undervalues	undervalue	VBZ	pb=undervalue.01	4	ccomp	4:A1=PPT
7	the	the	DT	_	8	det	_
8	opportunities	opportunity	NNS	_	6	dobj	6:A1=PPT
9	we	we	PRP	_	10	nsubj	10:A0
10	think	think	VBP	pb=think.01	8	rcmod	_
11	AstraZeneca	astrazeneca	NNP	_	13	nsubj	13:A0=PAG
12	could	could	MD	_	13	aux	13:AM-MOD
13	have	have	VB	pb=have.03	10	ccomp	10:A1=PPT
14	as	as	IN	p2=RB	13	prep	13:AM-PRD
15	an	an	DT	_	17	det	_
16	independent	independent	JJ	p2=NN	17	amod	_
17	company	company	NN	_	14	pobj	_
18	.	.	.	_	4	punct	_
19	"	"	''	_	4	punct	_

1	Secondly	secondly	RB	_	4	advmod	4:AM-DIS
2	,	,	,	_	4	punct	_
3	we	we	PRP	_	4	nsubj	4:A0
4	think	think	VBP	pb=think.01	0	root	_
5	there	there	EX	p2=RB	6	expl	_
6	is	be	VBZ	pb=be.02	4	ccomp	4:A1=PPT
7	a	a	DT	_	13	det	_
8	long	long	JJ	_	13	amod	_
9	,	,	,	_	13	punct	_
10	drawn	draw	VBN	_	12	hmod	_
11	-	-	HYPH	_	12	hyph	_
12	out	out	RP	_	13	amod	_
13	process	process	NN	_	6	attr	6:A1=PPT
14	,	,	,	_	6	punct	_
15	with	with	IN	_	6	prep	_
16	very	very	RB	_	17	advmod	_
17	considerable	considerable	JJ	_	19	amod	_
18	execution	execution	NN	_	19	nn	_
19	risk	risk	NN	_	15	pobj	_
20	...	..	.	p2=:	4	punct	_

1	and	and	CC	_	5	cc	5:AM-DIS
2	thirdly	thirdly	RB	_	5	advmod	5:AM-DIS
3	,	,	,	_	5	punct	_
4	we	we	PRP	_	5	nsubj	5:A0
5	think	think	VBP	pb=think.01	0	root	_
6	there	there	EX	_	7	expl	_
7	is	be	VBZ	pb=be.02	5	ccomp	5:A1=PPT
8	a	a	DT	_	11	det	_
9	clearly	clearly	RB	_	10	advmod	_
10	disruptive	disruptive	JJ	_	11	amod	_
11	element	element	NN	_	7	attr	7:A1=PPT
12	in	in	IN	_	11	prep	_
13	how	how	WRB	_	17	advmod	17:R-AM-MNR
14	we	we	PRP	_	17	nsubj	17:A0=PAG
15	can	can	MD	_	17	aux	17:AM-MOD
16	best	well	RBS	p2=RB	17	advmod	17:AM-MNR
17	create	create	VB	pb=create.01	12	pcomp	_
18	value	value	NN	_	17	dobj	17:A1=PPT
19	for	for	IN	_	18	prep	_
20	shareholders	shareholder	NNS	_	19	pobj	_
21	and	and	CC	_	20	cc	_
22	society	society	NN	_	20	conj	_
23	by	by	IN	_	17	prep	17:AM-MNR
24	disrupting	disrupt	VBG	pb=disrupt.01	23	pcomp	_
25	the	the	DT	_	26	det	_
26	way	way	NN	_	24	dobj	24:A1=PPT;28:AM-MNR
27	we	we	PRP	_	28	nsubj	28:A0=PAG
28	get	get	VBP	pb=get.01	26	rcmod	_
29	medicines	medicine	NNS	_	28	dobj	28:A1=PPT
30	to	to	IN	_	28	prep	_
31	the	the	DT	_	32	det	_
32	market	market	NN	_	30	pobj	_
33	.	.	.	_	5	punct	_

1	"	"	``	p2=''	8	punct	_
2	On	on	IN	p2=NNP	8	prep	8:AM-TMP
3	Sunday	sunday	NNP	_	2	pobj	_
4	,	,	,	_	8	punct	_
5	Pfizer	pfizer	NNP	_	6	nn	_
6	told AstraZeneca	told astrazeneca	NNP	p2=VBD	16	nsubj	_
7	it	it	PRP	_	8	nsubj	8:A0=PAG
8	had	have	VBD	pb=have.03	0	root	_
9	until	until	IN	_	8	prep	8:AM-TMP
10	5	0	CD	_	11	num	_
11	pm	pm	NN	_	9	pobj	_
12	on	on	IN	_	11	prep	_
13	May	may	NNP	_	12	pobj	_
14	26	0	CD	_	13	num	_
15	to	to	TO	_	16	aux	_
16	make	make	VB	pb=make.05	8	xcomp	_
17	a	a	DT	_	18	det	_
18	decision	decision	NN	_	16	dobj	16:AM-PRR
19	.	.	.	_	8	punct	_

1	Mr	mr	NNP	_	2	nn	_
2	Johansson	johansson	NNP	_	3	nsubj	3:A0
3	said	say	VBD	pb=say.01	0	root	_
4	he	he	PRP	_	7	nsubj	7:A0=PAG
5	had	have	VBD	_	7	aux	_
6	had	have	VBN	_	7	aux	_
7	made	make	VBN	pb=make.02	3	ccomp	3:A1=PPT
8	it	it	PRP	_	9	nsubj	_
9	clear	clear	JJ	_	7	ccomp	7:A1=PRD
10	that	that	IN	_	15	complm	_
11	his	his	PRP$	_	12	poss	_
12	board	board	NN	_	15	nsubj	15:A0=PAG
13	could	could	MD	_	15	aux	15:AM-MOD
14	only	only	RB	_	15	advmod	15:AM-ADV
15	recommend	recommend	VB	pb=recommend.01	9	advcl	_
16	a	a	DT	_	17	det	_
17	bid	bid	NN	_	15	dobj	15:A1=PPT;19:A1=PPT
18	that	that	WDT	p2=DT	19	nsubj	19:R-A1
19	was	be	VBD	pb=be.01	17	rcmod	_
20	at	at	IN	p2=RB	21	advmod	_
21	least	least	RBS	p2=JJS	22	advmod	_
22	10	0	CD	_	23	num	_
23	%	%	NN	_	24	npadvmod	_
24	above	above	IN	_	19	prep	19:A2=PRD
25	an	an	DT	_	26	det	_
26	offer	offer	NN	_	24	pobj	_
27	of	of	IN	_	26	prep	_
28	£53.50	£0	NNS	p2=NN	27	pobj	29:A1=PRD
29	made	make	VBN	pb=make.01	28	partmod	_
30	by	by	IN	_	29	agent	29:A0=PAG
31	Pfizer	pfizer	NNP	_	30	pobj	_
32	on	on	IN	_	29	prep	29:AM-TMP
33	Friday	friday	NNP	_	34	nn	_
34	evening	evening	NN	_	32	pobj	_
35	.	.	.	_	3	punct	_

1	AstraZeneca	astrazeneca	NNP	p2=JJ	2	nn	_
2	shares	share	NNS	_	3	nsubj	3:A1=PPT
3	plunged	plunge	VBD	p2=VBN|pb=plunge.02	0	root	_
4	by	by	IN	_	3	prep	3:A2=LOC
5	more	more	JJR	_	7	amod	_
6	than	than	IN	_	7	quantmod	_
7	14	0	CD	_	8	num	_
8	%	%	NN	_	4	pobj	_
9	in	in	IN	_	3	prep	3:AM-TMP
10	early	early	JJ	_	12	amod	_
11	Monday	monday	NNP	_	12	nn	_
12	trading	trading	NN	_	9	pobj	_
13	,	,	,	_	3	punct	_
14	driving	drive	VBG	pb=drive.02	3	advcl	3:AM-ADV
15	its	its	PRP$	_	17	poss	_
16	market	market	NN	_	17	nn	_
17	value	value	NN	_	14	dobj	14:A1=PPT
18	down	down	IN	p2=RB	14	advmod	14:A2=PRD
19	to	to	IN	_	18	prep	_
20	£52.1bn	£0bn	CD	p2=NNP	19	pobj	_
21	,	,	,	_	20	punct	_
22	£17bn	£0bn	CD	p2=IN	23	npadvmod	_
23	less	less	JJR	_	20	amod	_
24	than	than	IN	_	23	prep	_
25	the	the	DT	_	26	det	_
26	value	value	NN	_	24	pobj	29:A1=PPT
27	Pfizer	pfizer	NNP	_	29	nsubj	29:A0=PAG
28	had	have	VBD	_	29	aux	_
29	put	put	VBN	pb=put.01	26	rcmod	_
30	on	on	IN	_	29	prep	29:A2=GOL
31	the	the	DT	_	32	det	_
32	company	company	NN	_	30	pobj	_
33	.	.	.	_	3	punct	_

1	On	on	IN	_	10	prep	10:AM-TMP
2	May	may	NNP	_	1	pobj	_
3	2	0	CD	_	2	num	_
4	,	,	,	_	10	punct	_
5	New	new	NNP	_	6	nn	_
6	York	york	NNP	p2=NN	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	based	base	VBN	_	9	amod	_
9	Pfizer	pfizer	NNP	_	10	nsubj	10:A0=PAG
10	made	make	VBD	pb=make.01	0	root	_
11	an	an	DT	_	12	det	_
12	offer	offer	NN	_	10	dobj	24:A1;10:AM-PRR
13	of	of	IN	_	12	prep	_
14	£63bn	£63bn	NNP	p2=NN	19	nn	_
15	(	(	-LRB-	_	14	punct	_
16	$	$	$	p2=``	17	nmod	_
17	106bn	0bn	CD	p2=NNP	14	appos	_
18	)	)	-RRB-	_	19	punct	_
19	 for AstraZeneca	 for astrazeneca	NNP	p2=NN	13	pobj	_
20	,	,	,	_	12	punct	_
21	which	which	WDT	_	24	dobj	24:R-A1
22	the	the	DT	_	23	det	_
23	board	board	NN	_	24	nsubj	24:A0=PAG
24	rejected	reject	VBD	p2=VBN|pb=reject.01	12	rcmod	_
25	"	"	``	_	24	punct	_
26	without	without	IN	_	24	prep	24:AM-MNR
27	hesitation	hesitation	NN	_	26	pobj	_
28	"	"	''	_	24	punct	_
29	.	.	.	_	10	punct	_

1	Investors	investor	NNS	_	2	nsubj	2:A0=PAG;5:A0=PAG
2	backed	back	VBD	p2=VBN|pb=back.01	0	root	_
3	AstraZeneca	astrazeneca	NNP	_	2	dobj	2:A1=PPT
4	in	in	IN	_	2	prep	2:AM-MNR
5	rejecting	reject	VBG	pb=reject.01	4	pcomp	_
6	the	the	DT	_	12	det	_
7	cash	cash	NN	_	12	nn	_
8	-	-	HYPH	_	7	hyph	_
9	and	and	CC	_	7	cc	_
10	-	-	HYPH	_	11	hyph	_
11	stock	stock	NN	_	7	conj	_
12	approach	approach	NN	_	5	dobj	5:A1=PPT
13	worth	worth	JJ	p2=NN	12	amod	_
14	£50	£0	IN	p2=,	12	prep	_
15	a	a	DT	_	16	det	_
16	share	share	NN	_	14	pobj	_
17	,	,	,	_	2	punct	_
18	but	but	CC	_	2	cc	_
19	many	many	JJ	_	20	nsubj	20:A0
20	said	say	VBD	pb=say.01	2	conj	_
21	they	they	PRP	_	23	nsubj	23:A0=PAG
22	would	would	MD	_	23	aux	23:AM-MOD
23	want	want	VB	pb=want.01	20	ccomp	20:A1=PPT
24	it	it	PRP	_	26	nsubj	26:A0=PAG
25	to	to	TO	_	26	aux	_
26	engage	engage	VB	pb=engage.01	23	ccomp	23:A1=PPT
27	if	if	IN	_	29	mark	_
28	Pfizer	pfizer	NNP	_	29	nsubj	29:A1=PPT
29	came	come	VBD	pb=come.01	26	advcl	26:AM-ADV
30	back	back	RB	p2=RP	29	advmod	29:AM-DIR
31	with	with	IN	_	29	prep	29:AM-MNR
32	an	an	DT	_	34	det	_
33	improved	improved	JJ	p2=VBN	34	amod	_
34	offer	offer	NN	_	31	pobj	_
35	.	.	.	_	20	punct	_

1	Pfizer	pfizer	NNP	_	3	nsubj	3:A0;19:A0=PAG
2	has	have	VBZ	_	3	aux	_
3	said	say	VBD	p2=VBN|pb=say.01	0	root	_
4	it	it	PRP	_	7	nsubj	7:A0=PAG
5	will	will	MD	_	7	aux	7:AM-MOD
6	not	not	RB	_	7	neg	7:AM-NEG
7	make	make	VB	pb=make.02	3	ccomp	3:A1=PPT
8	a	a	DT	_	10	det	_
9	hostile	hostile	JJ	_	10	amod	_
10	offer	offer	NN	_	7	dobj	7:AM-PRR
11	directly	directly	RB	_	7	advmod	7:AM-MNR
12	to	to	IN	_	7	prep	7:A1=PRD
13	AstraZeneca	astrazeneca	NNP	_	14	nn	_
14	shareholders	shareholder	NNS	_	12	pobj	_
15	,	,	,	_	3	punct	_
16	and	and	CC	_	3	cc	_
17	would	would	MD	_	19	aux	19:AM-MOD
18	only	only	RB	_	19	advmod	19:AM-ADV
19	proceed	proceed	VB	pb=proceed.01	3	conj	_
20	with	with	IN	_	19	prep	19:A1=PPT
21	an	an	DT	_	22	det	_
22	offer	offer	NN	_	20	pobj	_
23	with	with	IN	_	22	prep	_
24	the	the	DT	_	25	det	_
25	recommendation	recommendation	NN	_	23	pobj	_
26	of	of	IN	_	25	prep	_
27	AstraZeneca	astrazeneca	NNP	_	29	poss	_
28	's	's	POS	_	27	possessive	_
29	board	board	NN	_	26	pobj	_
30	.	.	.	_	3	punct	_

1	Sky	sky	NNP	_	3	nn	_
2	News	news	NNP	_	3	nn	_
3	City	city	NNP	_	6	nn	_
4	Editor	editor	NNP	_	6	nn	_
5	Mark	mark	NNP	_	6	nn	_
6	Kleinman	kleinman	NNP	_	7	nsubj	7:A0
7	said	say	VBD	pb=say.01	0	root	_
8	:	:	:	_	7	punct	_
9	"	"	``	_	7	punct	_
10	The	the	DT	_	12	det	_
11	AstraZeneca	astrazeneca	NNP	_	12	nn	_
12	board	board	NN	_	14	nsubj	14:A0=PAG
13	has	have	VBZ	_	14	aux	_
14	highlighted	highlight	VBN	pb=highlight.01	7	ccomp	7:A1=PPT
15	the	the	DT	_	17	det	_
16	inherent	inherent	JJ	_	17	amod	_
17	risks	risk	NNS	_	14	dobj	14:A1=PPT
18	in	in	IN	_	17	prep	_
19	doing	do	VBG	pb=do.02	18	pcomp	_
20	a	a	DT	_	21	det	_
21	deal	deal	NN	_	19	dobj	19:A1=PPT
22	with	with	IN	_	21	prep	_
23	Pfizer	pfizer	NNP	_	22	pobj	_
24	at	at	IN	_	19	prep	19:AM-MNR
25	any	any	DT	_	26	det	_
26	price	price	NN	_	24	pobj	_
27	-	-	:	p2=,	23	punct	_
28	the	the	DT	_	29	det	_
29	risk	risk	NN	_	26	appos	_
30	to	to	IN	_	29	prep	_
31	jobs	job	NNS	_	30	pobj	35:A1=PPT
32	that	that	WDT	p2=DT	35	nsubjpass	35:R-A1
33	would	would	MD	_	35	aux	35:AM-MOD
34	be	be	VB	_	35	auxpass	_
35	triggered	trigger	VBN	pb=trigger.01	31	rcmod	_
36	from	from	IN	_	35	prep	_
37	a	a	DT	_	38	det	_
38	merger	merger	NN	_	36	pobj	_
39	of	of	IN	_	38	prep	_
40	this	this	DT	_	41	det	_
41	kind	kind	NN	_	39	pobj	_
42	.	.	.	_	7	punct	_

1	"	"	``	_	11	punct	_
2	But	but	CC	_	11	cc	11:AM-DIS
3	unusually	unusually	RB	_	4	advmod	_
4	in	in	IN	p2=RB	11	prep	11:AM-LOC
5	AstraZeneca	astrazeneca	NNP	_	7	poss	_
6	's	's	POS	_	5	possessive	_
7	statement	statement	NN	_	4	pobj	_
8	,	,	,	_	11	punct	_
9	it	it	PRP	_	11	nsubj	11:A0=PAG
10	has	have	VBZ	_	11	aux	_
11	put	put	VBN	pb=put.01	0	root	_
12	a	a	DT	_	14	det	_
13	price	price	NN	_	14	nn	_
14	tag	tag	NN	_	11	dobj	11:A1=PPT
15	on	on	IN	_	11	prep	11:A2=GOL
16	itself	itself	PRP	_	15	pobj	_
17	...	..	.	p2=NFP	11	punct	_

1	it	it	PRP	_	2	nsubj	2:A0
2	says	say	VBZ	pb=say.01	0	root	_
3	it	it	PRP	_	6	nsubj	9:A0;6:A1=PPT
4	would	would	MD	_	6	aux	6:AM-MOD
5	only	only	RB	_	6	advmod	6:AM-ADV
6	be	be	VB	pb=be.01	2	ccomp	2:A1=PPT
7	prepared	prepared	JJ	p2=VBN	6	acomp	6:A2=PRD
8	to	to	TO	_	9	aux	_
9	make	make	VB	pb=make.LV	7	xcomp	_
10	a	a	DT	_	11	det	_
11	recommendation	recommendation	NN	_	9	dobj	9:AM-PRR
12	to	to	IN	_	11	prep	_
13	shareholders	shareholder	NNS	_	12	pobj	_
14	if	if	IN	_	19	mark	_
15	the	the	DT	_	16	det	_
16	board	board	NN	_	19	nsubj	19:A1=PPT
17	of	of	IN	_	16	prep	_
18	Pfizer	pfizer	NNP	_	17	pobj	_
19	were	be	VBD	pb=be.01	6	advcl	6:AM-ADV
20	to	to	TO	_	21	aux	_
21	make	make	VB	pb=make.02	19	xcomp	19:A2=PRD
22	an	an	DT	_	23	det	_
23	offer	offer	NN	_	21	dobj	25:A1=PPT;21:AM-PRR
24	that	that	WDT	p2=DT	25	nsubj	25:R-A1
25	was	be	VBD	pb=be.01	23	rcmod	_
26	at	at	IN	p2=RB	27	advmod	_
27	least	least	RBS	p2=JJS	28	advmod	_
28	10	0	CD	_	29	num	_
29	%	%	NN	_	30	npadvmod	_
30	above	above	IN	_	25	prep	25:A2=PRD
31	the	the	DT	_	32	det	_
32	£53.50	£0	NN	p2=CD	30	pobj	37:A1=PRD
33	per	per	IN	_	32	prep	_
34	share	share	NN	_	33	pobj	_
35	that	that	WDT	_	37	nsubjpass	37:R-A1
36	was	be	VBD	_	37	auxpass	_
37	made	make	VBN	pb=make.01	32	rcmod	_
38	privately	privately	RB	_	37	advmod	37:AM-MNR
39	on	on	IN	_	37	prep	37:AM-TMP
40	Friday	friday	NNP	_	39	pobj	_
41	.	.	.	_	2	punct	_
42	"	"	''	_	2	punct	_

1	That	that	DT	_	3	nsubj	3:A0=PAG
2	would	would	MD	_	3	aux	3:AM-MOD
3	put	put	VB	pb=put.01	0	root	_
4	a	a	DT	_	6	det	_
5	price	price	NN	_	6	nn	_
6	tag	tag	NN	_	3	dobj	3:A1=PPT
7	on	on	IN	_	3	prep	3:A2=GOL
8	AstraZeneca	astrazeneca	NNP	_	7	pobj	_
9	of	of	IN	_	8	prep	_
10	about	about	IN	p2=RB	11	advmod	_
11	£59	£0	CD	p2=PDT	9	pobj	_
12	a	a	DT	_	15	det	_
13	share	share	NN	_	15	hmod	_
14	-	-	HYPH	p2=,	15	hyph	_
15	well	well	NN	p2=RB	3	dobj	_
16	over	over	IN	_	15	prep	_
17	£70bn	£0bn	NN	p2=NNP	16	pobj	_
18	.	.	.	_	3	punct	_

1	"	"	``	_	6	punct	_
2	The	the	DT	_	5	det	_
3	latest	late	JJS	p2=RBS	5	amod	_
4	rejected	reject	VBN	p2=VBD|pb=reject.01	5	amod	_
5	bid	bid	NN	p2=VBD	6	nsubj	6:A0=PAG;4:A1=PPT
6	increased	increase	VBD	pb=increase.01	0	root	_
7	the	the	DT	_	9	det	_
8	cash	cash	NN	_	9	nn	_
9	element	element	NN	_	6	dobj	6:A1=PPT
10	to	to	IN	_	6	prep	6:A4=GOL
11	45	0	CD	_	12	num	_
12	%	%	NN	_	10	pobj	_
13	,	,	,	_	6	punct	_
14	with	with	IN	_	6	prep	6:AM-ADV
15	AstraZeneca	astrazeneca	NNP	p2=JJ	16	nn	_
16	shareholders	shareholder	NNS	_	17	nsubj	17:A0=PAG;19:A0=PAG
17	set	set	VBN	p2=VBP|pb=set.08	14	pcomp	_
18	to	to	TO	_	19	aux	_
19	receive	receive	VB	pb=receive.01	17	xcomp	17:A1=PPT
20	1.747	0	CD	_	21	num	_
21	shares	share	NNS	_	19	dobj	19:A1=PPT
22	in	in	IN	_	19	prep	19:AM-LOC
23	the	the	DT	_	25	det	_
24	enlarged	enlarged	JJ	p2=VBN	25	amod	_
25	company	company	NN	_	22	pobj	_
26	for	for	IN	_	19	prep	19:A3
27	each	each	DT	_	26	pobj	_
28	of	of	IN	_	27	prep	_
29	their	their	PRP$	_	31	poss	_
30	AstraZeneca	astrazeneca	NNP	p2=JJ	31	nn	_
31	shares	share	NNS	_	28	pobj	_
32	and	and	CC	_	17	cc	_
33	2.476p	0p	CD	p2=LS	17	conj	_
34	in	in	IN	p2=RP	33	prep	_
35	cash	cash	NN	_	34	pobj	_
36	.	.	.	_	6	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0=PAG;4:A0=PAG
2	wants	want	VBZ	pb=want.01	0	root	_
3	to	to	TO	_	4	aux	_
4	create	create	VB	pb=create.01	2	xcomp	2:A1=PPT
5	the	the	DT	_	6	det	_
6	world	world	NN	_	10	poss	_
7	's	's	POS	_	6	possessive	_
8	largest	large	JJS	_	10	amod	_
9	drugs	drug	NNS	_	10	nn	_
10	company	company	NN	_	4	dobj	4:A1=PPT
11	,	,	,	_	4	punct	_
12	with	with	IN	_	4	prep	_
13	its	its	PRP$	_	14	poss	_
14	headquarters	headquarters	NN	p2=NNS	12	pobj	_
15	in	in	IN	_	14	prep	_
16	New	new	NNP	_	17	nn	_
17	York	york	NNP	_	15	pobj	_
18	and	and	CC	_	14	cc	_
19	a	a	DT	_	21	det	_
20	tax	tax	NN	_	21	nn	_
21	base	base	NN	_	14	conj	_
22	in	in	IN	_	21	prep	_
23	Britain	britain	NNP	_	22	pobj	_
24	.	.	.	_	2	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	16	nsubj	16:A0=PAG
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	5	nn	_
5	PLC	plc	NNP	_	3	pobj	_
6	(	(	-LRB-	_	2	punct	_
7	"	"	``	_	8	punct	_
8	AstraZeneca	astrazeneca	NNP	_	2	appos	_
9	"	"	''	_	8	punct	_
10	or	or	CC	_	8	cc	_
11	the	the	DT	_	13	det	_
12	"	"	``	_	13	punct	_
13	Company	company	NNP	p2=JJ	8	conj	_
14	"	"	''	_	13	punct	_
15	)	)	-RRB-	_	2	punct	_
16	notes	note	VBZ	pb=note.01	0	root	_
17	the	the	DT	_	18	det	_
18	announcement	announcement	NN	_	16	dobj	16:A1=PPT
19	by	by	IN	_	18	prep	_
20	Pfizer	pfizer	NNP	_	21	nn	_
21	Inc	inc	NNP	_	19	pobj	_
22	.	.	.	_	16	punct	_

1	(	(	-LRB-	_	3	punct	_
2	"	"	``	_	3	punct	_
3	Pfizer	pfizer	NNP	_	54	nn	_
4	"	"	''	_	3	punct	_
5	)	)	-RRB-	_	3	punct	_
6	of	of	IN	_	3	prep	_
7	its	its	PRP$	_	9	poss	_
8	final	final	JJ	_	9	amod	_
9	proposal	proposal	NN	_	6	pobj	_
10	(	(	-LRB-	_	9	punct	_
11	the	the	DT	_	14	det	_
12	"	"	``	_	14	punct	_
13	Final	final	JJ	p2=NNP	14	amod	_
14	Proposal	proposal	NN	p2=NNP	9	appos	_
15	"	"	''	_	14	punct	_
16	)	)	-RRB-	_	14	punct	_
17	,	,	,	_	14	punct	_
18	comprising	comprise	VBG	pb=comprise.01	14	partmod	_
19	£24.76	£0	CD	p2=NN	18	dobj	18:A2
20	in	in	IN	_	19	prep	_
21	cash	cash	NN	_	0	root	_
22	(	(	-LRB-	_	21	punct	_
23	45	0	CD	_	24	num	_
24	%	%	NN	_	21	appos	_
25	)	)	-RRB-	_	21	punct	_
26	and	and	CC	_	21	cc	_
27	1.747	0	CD	_	29	num	_
28	Pfizer	pfizer	NNP	_	29	nn	_
29	shares	share	NNS	_	21	conj	_
30	(	(	-LRB-	_	29	punct	_
31	55	0	CD	_	32	num	_
32	%	%	NN	_	29	appos	_
33	)	)	-RRB-	_	29	punct	_
34	per	per	IN	p2=CC	29	prep	_
35	AstraZeneca	astrazeneca	NNP	p2=NN	36	nn	_
36	share	share	NN	p2=NNP	34	pobj	_
37	,	,	,	_	29	punct	_
38	representing	represent	VBG	pb=represent.01	29	partmod	_
39	a	a	DT	_	40	det	_
40	value	value	NN	_	38	dobj	38:A1=PPT;47:A1=PPT
41	of	of	IN	_	40	prep	_
42	£55.00	£0	NN	p2=CD	41	pobj	_
43	per	per	IN	_	42	prep	_
44	AstraZeneca	astrazeneca	NNP	_	45	nn	_
45	share	share	NN	p2=VBP	43	pobj	_
46	(	(	-LRB-	_	40	punct	_
47	based	base	VBN	pb=base.02	40	partmod	_
48	on	on	IN	_	47	prep	47:A2=DIR
49	the	the	DT	_	51	det	_
50	closing	closing	NN	_	51	nn	_
51	price	price	NN	_	48	pobj	_
52	of	of	IN	_	51	prep	_
53	Pfizer	pfizer	NNP	p2=NN	54	nn	_
54	shares	share	NNS	_	52	pobj	_
55	on	on	IN	_	51	prep	_
56	16	0	CD	_	57	num	_
57	May	may	NNP	_	55	pobj	_
58	2014	0	CD	_	57	num	_
59	)	)	-RRB-	_	29	punct	_
60	.	.	.	_	3	punct	_

1	This	this	DT	_	2	det	_
2	proposal	proposal	NN	_	3	nsubj	3:A0=PAG;13:A1=PPT
3	undervalues	undervalue	VBZ	pb=undervalue.01	0	root	_
4	the	the	DT	_	5	det	_
5	Company	company	NNP	p2=NN	3	dobj	3:A1=PPT
6	and	and	CC	_	5	cc	_
7	its	its	PRP$	_	9	poss	_
8	attractive	attractive	JJ	_	9	amod	_
9	prospects	prospect	NNS	_	5	conj	_
10	and	and	CC	_	3	cc	_
11	has	have	VBZ	_	13	aux	_
12	been	be	VBN	_	13	auxpass	_
13	rejected	reject	VBN	pb=reject.01	3	conj	_
14	by	by	IN	_	13	agent	13:A0=PAG
15	the	the	DT	_	16	det	_
16	Board	board	NNP	_	14	pobj	_
17	of	of	IN	_	16	prep	_
18	AstraZeneca	astrazeneca	NNP	_	17	pobj	_
19	.	.	.	_	3	punct	_

1	Leif	leif	NNP	p2=IN	2	nn	_
2	Johansson	johansson	NNP	_	7	nsubj	7:A0
3	,	,	,	_	2	punct	_
4	Chairman	chairman	NNP	_	2	appos	_
5	of	of	IN	_	4	prep	_
6	AstraZeneca	astrazeneca	NNP	_	5	pobj	_
7	said	say	VBD	pb=say.01	0	root	_
8	:	:	:	_	7	punct	_
9	"	"	``	_	7	punct	_
10	Pascal	pascal	NNP	_	11	nn	_
11	Soriot	soriot	NNP	p2=''	17	nsubj	17:A0=PAG
12	,	,	,	_	11	punct	_
13	Marc	marc	NNP	_	14	nn	_
14	Dunoyer	dunoyer	NNP	_	11	conj	_
15	and	and	CC	_	14	cc	_
16	I	I	PRP	_	14	conj	_
17	had	have	VBD	pb=have.03	7	ccomp	7:A1=PPT
18	a	a	DT	_	20	det	_
19	lengthy	lengthy	JJ	_	20	amod	_
20	discussion	discussion	NN	_	17	dobj	17:A1=PPT
21	with	with	IN	_	20	prep	_
22	Pfizer	pfizer	NNP	p2=NN	21	pobj	_
23	over	over	IN	_	20	prep	_
24	the	the	DT	_	25	det	_
25	weekend	weekend	NN	_	23	pobj	_
26	about	about	IN	_	20	prep	_
27	the	the	DT	_	28	det	_
28	proposal	proposal	NN	_	26	pobj	30:AM-PRR
29	Pfizer	pfizer	NNP	p2=NN	30	nsubj	30:A0=PAG
30	made	make	VBD	pb=make.01	28	rcmod	_
31	on	on	IN	_	30	prep	30:AM-TMP
32	Friday	friday	NNP	_	33	nn	_
33	evening	evening	NN	_	31	pobj	_
34	at	at	IN	_	30	prep	30:AM-LOC
35	a	a	DT	_	36	det	_
36	value	value	NN	_	34	pobj	_
37	of	of	IN	_	36	prep	_
38	£53.50	£0	NN	p2=CD	37	pobj	_
39	per	per	IN	_	38	prep	_
40	share	share	NN	_	39	pobj	_
41	.	.	.	_	7	punct	_

1	"	"	``	_	7	punct	_
2	During	during	IN	_	7	prep	7:AM-TMP
3	this	this	DT	_	4	det	_
4	discussion	discussion	NN	_	2	pobj	_
5	,	,	,	_	7	punct	_
6	Pfizer	pfizer	NNP	_	7	nsubj	7:A0
7	said	say	VBD	pb=say.01	0	root	_
8	that	that	IN	_	11	complm	_
9	it	it	PRP	_	11	nsubj	11:A0=PAG
10	could	could	MD	_	11	aux	11:AM-MOD
11	consider	consider	VB	pb=consider.01	7	ccomp	7:A1=PPT
12	only	only	RB	p2=JJ	13	advmod	_
13	minor	minor	JJ	_	14	amod	_
14	improvements	improvement	NNS	_	11	dobj	11:A1
15	in	in	IN	_	14	prep	_
16	the	the	DT	_	18	det	_
17	financial	financial	JJ	_	18	amod	_
18	terms	term	NNS	_	15	pobj	_
19	of	of	IN	_	18	prep	_
20	the	the	DT	_	22	det	_
21	Friday	friday	NNP	_	22	nn	_
22	Proposal	proposal	NNP	p2=NN	19	pobj	_
23	.	.	.	_	7	punct	_

1	In	in	IN	_	5	prep	5:AM-ADV
2	response	response	NN	_	1	pobj	_
3	,	,	,	_	5	punct	_
4	we	we	PRP	_	5	nsubj	5:A0=CAU;8:A0=PAG
5	indicated	indicate	VBD	pb=indicate.01	0	root	_
6	,	,	,	_	5	punct	_
7	even	even	RB	_	8	advmod	8:AM-ADV
8	assuming	assume	VBG	pb=assume.02	5	advcl	5:AM-ADV
9	that	that	IN	p2=DT	17	complm	_
10	other	other	JJ	_	12	amod	_
11	key	key	JJ	_	12	amod	_
12	aspects	aspect	NNS	_	17	nsubj	17:A1=PPT
13	of	of	IN	_	12	prep	_
14	any	any	DT	_	15	det	_
15	proposal	proposal	NN	_	13	pobj	_
16	had	have	VBD	_	17	aux	_
17	been	be	VBN	pb=be.01	8	ccomp	8:A1=PPT
18	satisfactory	satisfactory	JJ	_	17	acomp	17:A2=PRD
19	,	,	,	_	17	punct	_
20	that	that	IN	_	37	mark	_
21	the	the	DT	_	22	det	_
22	price	price	NN	_	37	nsubj	39:A1=PPT;30:AM-LOC
23	at	at	IN	_	30	prep	30:R-AM-LOC
24	which	which	WDT	_	23	pobj	_
25	the	the	DT	_	26	det	_
26	Board	board	NNP	_	30	nsubj	33:A0=PAG;30:A1=PPT
27	of	of	IN	_	26	prep	_
28	AstraZeneca	astrazeneca	NNP	_	27	pobj	_
29	would	would	MD	_	30	aux	30:AM-MOD
30	be	be	VB	pb=be.01	22	rcmod	_
31	prepared	prepared	JJ	p2=VBN	30	acomp	30:A2=PRD
32	to	to	TO	_	33	aux	_
33	provide	provide	VB	pb=provide.01	31	xcomp	_
34	a	a	DT	_	35	det	_
35	recommendation	recommendation	NN	_	33	dobj	33:A1=PPT
36	would	would	MD	_	37	aux	_
37	have	have	VB	pb=have.02	17	conj	_
38	to	to	TO	_	39	aux	_
39	be	be	VB	pb=be.01	37	xcomp	_
40	more	more	JJR	_	42	amod	_
41	than	than	IN	_	42	quantmod	_
42	10	0	CD	_	43	num	_
43	%	%	NN	_	39	attr	39:A2=PRD
44	above	above	IN	_	43	prep	_
45	the	the	DT	_	46	det	_
46	level	level	NN	_	44	pobj	47:A1
47	contained	contain	VBN	p2=VBD|pb=contain.01	46	partmod	_
48	in	in	IN	_	47	prep	47:A0
49	Pfizer	pfizer	NNP	_	52	poss	_
50	's	's	POS	_	49	possessive	_
51	Friday	friday	NNP	_	52	nn	_
52	Proposal	proposal	NNP	_	48	pobj	_
53	.	.	.	_	5	punct	_
54	"	"	''	_	5	punct	_

1	The	the	DT	_	3	det	_
2	Final	final	JJ	p2=NNP	3	amod	_
3	Proposal	proposal	NNP	p2=NN	4	nsubj	4:A1=PPT
4	is	be	VBZ	pb=be.01	0	root	_
5	a	a	DT	_	7	det	_
6	minor	minor	JJ	_	7	amod	_
7	improvement	improvement	NN	_	4	attr	9:A0;11:A1=PPT;23:A1=PPT;4:A2=PRD
8	which	which	WDT	_	9	nsubj	9:R-A0;11:R-A1;23:R-A1
9	continues	continue	VBZ	pb=continue.01	7	rcmod	_
10	to	to	TO	_	11	aux	_
11	fall	fall	VB	pb=fall.01	9	xcomp	9:A1=PPT
12	short	short	RB	p2=JJ	11	advmod	11:A4=GOL
13	of	of	IN	_	12	prep	_
14	the	the	DT	_	15	det	_
15	Board	board	NNP	_	17	poss	_
16	's	's	POS	_	15	possessive	_
17	view	view	NN	_	13	pobj	_
18	of	of	IN	_	17	prep	_
19	value	value	NN	_	18	pobj	_
20	and	and	CC	_	9	cc	_
21	has	have	VBZ	_	23	aux	_
22	been	be	VBN	_	23	auxpass	_
23	rejected	reject	VBN	pb=reject.01	9	conj	_
24	.	.	.	_	4	punct	_

1	"	"	``	p2=''	11	punct	_
2	"	"	``	_	11	punct	_
3	Pfizer	pfizer	NNP	_	5	poss	_
4	's	's	POS	p2=''	3	possessive	_
5	approach	approach	NN	_	11	nsubj	11:A1=PPT;16:A1=PPT
6	throughout	throughout	IN	_	5	prep	_
7	its	its	PRP$	_	8	poss	_
8	pursuit	pursuit	NN	_	6	pobj	_
9	of	of	IN	_	8	prep	_
10	AstraZeneca	astrazeneca	NNP	_	9	pobj	_
11	appears	appear	VBZ	pb=appear.02	0	root	_
12	to	to	TO	_	16	aux	_
13	have	have	VB	_	16	aux	_
14	been	be	VBN	_	16	auxpass	_
15	fundamentally	fundamentally	RB	_	16	advmod	16:AM-MNR
16	driven	drive	VBN	pb=drive.02	11	xcomp	11:C-A1
17	by	by	IN	_	16	agent	16:A0=PAG
18	the	the	DT	_	21	det	_
19	corporate	corporate	JJ	_	21	amod	_
20	financial	financial	JJ	_	21	amod	_
21	benefits	benefit	NNS	_	17	pobj	_
22	to	to	IN	_	21	prep	_
23	its	its	PRP$	_	24	poss	_
24	shareholders	shareholder	NNS	_	22	pobj	_
25	of	of	IN	_	24	prep	_
26	cost	cost	NN	p2=JJ	27	nn	_
27	savings	saving	NNS	_	25	pobj	_
28	and	and	CC	_	27	cc	_
29	tax	tax	NN	_	30	nn	_
30	minimisation	minimisation	NN	_	27	conj	_
31	.	.	.	_	11	punct	_

1	"	"	``	p2=''	25	punct	_
2	From	from	IN	_	25	prep	25:AM-TMP
3	our	our	PRP$	_	5	poss	_
4	first	#ord#	JJ	_	5	amod	_
5	meeting	meeting	NN	_	2	pobj	_
6	in	in	IN	_	5	prep	_
7	January	january	NNP	_	6	pobj	_
8	to	to	IN	_	2	prep	_
9	our	our	PRP$	_	11	poss	_
10	latest	late	JJS	_	11	amod	_
11	discussion	discussion	NN	_	8	pobj	_
12	yesterday	yesterday	NN	_	2	npadvmod	_
13	,	,	,	_	2	punct	_
14	and	and	CC	_	2	cc	_
15	in	in	IN	_	25	prep	25:AM-LOC
16	the	the	DT	_	19	det	_
17	numerous	numerous	JJ	_	19	amod	_
18	phone	phone	NN	_	19	nn	_
19	calls	call	NNS	p2=VBZ	15	pobj	_
20	in	in	IN	p2=RP	19	prep	_
21	between	between	IN	p2=NN	19	prep	_
22	,	,	,	_	25	punct	_
23	Pfizer	pfizer	NNP	_	25	nsubj	27:A0=PAG;25:A1=PAG
24	has	have	VBZ	_	25	aux	_
25	failed	fail	VBN	pb=fail.01	0	root	_
26	to	to	TO	_	27	aux	_
27	make	make	VB	pb=make.02	25	xcomp	25:A2=PPT
28	a	a	DT	_	35	det	_
29	compelling	compelling	JJ	_	35	amod	_
30	strategic	strategic	JJ	_	35	amod	_
31	,	,	,	_	30	punct	_
32	business	business	NN	_	35	nn	_
33	or	or	CC	_	32	cc	_
34	value	value	NN	_	32	conj	_
35	case	case	NN	_	27	dobj	27:A1=PRD
36	.	.	.	_	25	punct	_
37	"	"	''	_	25	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	p2=NN	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	firm	firm	JJ	p2=RB	3	acomp	3:A2=PRD
5	in	in	IN	_	4	prep	_
6	its	its	PRP$	_	7	poss	_
7	conviction	conviction	NN	_	5	pobj	_
8	as	as	IN	p2=RB	7	prep	_
9	to	to	IN	_	8	prep	_
10	the	the	DT	_	12	det	_
11	appropriate	appropriate	JJ	_	12	amod	_
12	terms	term	NNS	_	9	pobj	_
13	to	to	TO	_	14	aux	_
14	recommend	recommend	VB	pb=recommend.01	12	infmod	_
15	to	to	IN	_	14	prep	14:A2=GOL
16	shareholders	shareholder	NNS	_	15	pobj	_
17	.	.	.	_	3	punct	_

1	"	"	``	p2=''	5	punct	_
2	"	"	``	p2=''	5	punct	_
3	AstraZeneca	astrazeneca	NNP	_	5	nsubj	5:A0=PAG
4	has	have	VBZ	_	5	aux	_
5	created	create	VBN	pb=create.01	0	root	_
6	a	a	DT	_	7	det	_
7	culture	culture	NN	_	5	dobj	5:A1=PPT
8	of	of	IN	_	7	prep	_
9	innovation	innovation	NN	_	8	pobj	_
10	,	,	,	_	7	punct	_
11	with	with	IN	_	7	prep	_
12	science	science	NN	_	11	pobj	_
13	at	at	IN	_	5	prep	5:AM-LOC
14	the	the	DT	_	15	det	_
15	heart	heart	NN	_	13	pobj	24:A0;22:A1
16	of	of	IN	_	15	prep	_
17	its	its	PRP$	_	18	poss	_
18	operations	operation	NNS	_	16	pobj	_
19	,	,	,	_	15	punct	_
20	which	which	WDT	_	22	nsubj	24:R-A0;22:R-A1
21	will	will	MD	_	22	aux	22:AM-MOD
22	continue	continue	VB	pb=continue.01	15	rcmod	_
23	to	to	TO	_	24	aux	_
24	create	create	VB	pb=create.01	22	xcomp	22:A1=PPT
25	significant	significant	JJ	_	26	amod	_
26	value	value	NN	_	24	dobj	24:A1=PPT
27	for	for	IN	_	24	prep	24:A3=GOL
28	patients	patient	NNS	_	27	pobj	_
29	,	,	,	_	28	punct	_
30	shareholders	shareholder	NNS	_	28	conj	_
31	and	and	CC	_	30	cc	_
32	all	all	DT	_	33	det	_
33	stakeholders	stakeholder	NNS	_	30	conj	_
34	of	of	IN	_	33	prep	_
35	AstraZeneca	astrazeneca	NNP	_	34	pobj	_
36	.	.	.	_	5	punct	_

1	"	"	``	p2=''	16	punct	_
2	"	"	``	_	16	punct	_
3	As	as	IN	_	16	prep	16:AM-ADV
4	an	an	DT	_	6	det	_
5	independent	independent	JJ	p2=NN	6	amod	_
6	company	company	NN	_	3	pobj	_
7	,	,	,	_	16	punct	_
8	the	the	DT	_	10	det	_
9	entire	entire	JJ	_	10	amod	_
10	value	value	NN	_	16	nsubj	16:A1=PPT
11	of	of	IN	_	10	prep	_
12	AstraZeneca	astrazeneca	NNP	_	14	poss	_
13	's	's	POS	_	12	possessive	_
14	pipeline	pipeline	NN	_	11	pobj	_
15	will	will	MD	_	16	aux	16:AM-MOD
16	accrue	accrue	VB	pb=accrue.01	0	root	_
17	to	to	IN	_	16	prep	_
18	our	our	PRP$	_	19	poss	_
19	shareholders	shareholder	NNS	_	17	pobj	_
20	.	.	.	_	16	punct	_

1	Under	under	IN	_	12	prep	12:AM-LOC
2	Pfizer	pfizer	NNP	_	5	poss	_
3	's	's	POS	_	2	possessive	_
4	Final	final	JJ	p2=NNP	5	amod	_
5	Proposal	proposal	NNP	p2=NN	1	pobj	_
6	,	,	,	_	12	punct	_
7	this	this	DT	_	8	det	_
8	value	value	NN	_	12	nsubjpass	12:A1=PPT
9	would	would	MD	_	12	aux	12:AM-MOD
10	be	be	VB	_	12	auxpass	_
11	significantly	significantly	RB	_	12	advmod	12:AM-MNR
12	diluted	dilute	VBN	pb=dilute.01	0	root	_
13	.	.	.	_	12	punct	_

1	"	"	``	p2=''	5	punct	_
2	"	"	``	_	26	punct	_
3	We	we	PRP	_	5	nsubj	5:A0=PAG
4	have	have	VBP	_	5	aux	_
5	rejected	reject	VBN	pb=reject.01	0	root	_
6	Pfizer	pfizer	NNP	_	9	poss	_
7	's	's	POS	_	6	possessive	_
8	Final	final	JJ	p2=NNP	9	amod	_
9	Proposal	proposal	NN	p2=NNP	5	dobj	5:A1=PPT
10	because	because	IN	_	12	mark	_
11	it	it	PRP	_	12	nsubj	16:A0=PAG;12:A1=PPT
12	is	be	VBZ	pb=be.01	5	advcl	5:AM-CAU
13	inadequate	inadequate	JJ	_	12	acomp	12:A2=PRD
14	and	and	CC	_	12	cc	_
15	would	would	MD	_	16	aux	16:AM-MOD
16	present	present	VB	p2=JJ|pb=present.01	12	conj	_
17	significant	significant	JJ	_	18	amod	_
18	risks	risk	NNS	_	16	dobj	16:A1=PPT
19	for	for	IN	_	18	prep	_
20	shareholders	shareholder	NNS	_	19	pobj	_
21	,	,	,	_	16	punct	_
22	while	while	IN	_	24	mark	_
23	also	also	RB	_	24	advmod	_
24	having	have	VBG	pb=have.03	16	advcl	_
25	serious	serious	JJ	_	26	amod	_
26	consequences	consequence	NNS	_	24	dobj	24:A1=PPT
27	for	for	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	Company	company	NNP	p2=NN	27	pobj	_
30	,	,	,	_	29	punct	_
31	our	our	PRP$	_	32	poss	_
32	employees	employee	NNS	_	29	conj	_
33	and	and	CC	_	32	cc	_
34	the	the	DT	_	38	det	_
35	life	life	NN	_	37	hmod	_
36	-	-	HYPH	_	37	hyph	_
37	sciences	science	NNS	_	38	nn	_
38	sector	sector	NN	_	32	conj	_
39	in	in	IN	_	38	prep	_
40	the	the	DT	_	41	det	_
41	UK	uk	NNP	_	39	pobj	_
42	,	,	,	_	41	punct	_
43	Sweden	sweden	NNP	_	41	conj	_
44	and	and	CC	_	43	cc	_
45	the	the	DT	_	46	det	_
46	US	us	NNP	_	43	conj	_
47	.	.	.	_	5	punct	_

1	"	"	``	p2=''	14	punct	_
2	After	after	IN	_	14	prep	14:AM-TMP
3	the	the	DT	_	4	det	_
4	close	close	NN	p2=NNPS	2	pobj	_
5	of	of	IN	_	4	prep	_
6	business	business	NN	_	5	pobj	_
7	on	on	IN	_	4	prep	_
8	16	0	CD	_	9	num	_
9	May	may	NNP	_	7	pobj	_
10	2014	0	CD	_	9	num	_
11	,	,	,	_	14	punct	_
12	the	the	DT	_	13	det	_
13	Board	board	NNP	_	14	nsubj	14:A0=PAG
14	received	receive	VBD	pb=receive.01	0	root	_
15	a	a	DT	_	16	det	_
16	letter	letter	NN	_	14	dobj	17:A0;14:A1=PPT
17	containing	contain	VBG	pb=contain.01	16	partmod	_
18	a	a	DT	_	21	det	_
19	revised	revise	VBN	p2=JJ|pb=revise.01	21	amod	_
20	non-binding	non-binding	JJ	_	21	amod	_
21	proposal	proposal	NN	_	17	dobj	17:A1;19:A1=PPT
22	from	from	IN	_	21	prep	_
23	Pfizer	pfizer	NNP	_	24	nsubj	24:A1=PPT
24	comprising	comprise	VBG	pb=comprise.01	22	pcomp	_
25	£21.57	£0	NN	p2=CD	24	dobj	24:A2
26	in	in	IN	_	24	prep	_
27	cash	cash	NN	_	26	pobj	_
28	(	(	-LRB-	_	30	punct	_
29	40	0	CD	_	30	num	_
30	%	%	NN	_	22	pobj	_
31	)	)	-RRB-	_	30	punct	_
32	and	and	CC	_	30	cc	_
33	1.845	0	CD	_	35	num	_
34	Pfizer	pfizer	NNP	_	35	nn	_
35	shares	share	NNS	_	30	conj	_
36	(	(	-LRB-	_	35	punct	_
37	60	0	CD	_	38	num	_
38	%	%	NN	_	35	appos	_
39	)	)	-RRB-	_	35	punct	_
40	per	per	IN	p2=CC	30	prep	_
41	AstraZeneca	astrazeneca	NNP	p2=NN	42	nn	_
42	share	share	NN	p2=NNP	40	pobj	_
43	,	,	,	_	30	punct	_
44	representing	represent	VBG	pb=represent.01	30	partmod	_
45	a	a	DT	_	46	det	_
46	value	value	NN	_	44	dobj	44:A1=PPT;53:A1=PPT
47	of	of	IN	_	46	prep	_
48	£53.50	£0	NN	p2=CD	47	pobj	_
49	per	per	IN	_	48	prep	_
50	AstraZeneca	astrazeneca	NNP	_	51	nn	_
51	share	share	NN	p2=VBP	49	pobj	_
52	(	(	-LRB-	_	46	punct	_
53	based	base	VBN	pb=base.02	46	partmod	_
54	on	on	IN	_	53	prep	53:A2=DIR
55	the	the	DT	_	57	det	_
56	closing	closing	NN	_	57	nn	_
57	price	price	NN	_	54	pobj	_
58	of	of	IN	_	57	prep	_
59	Pfizer	pfizer	NNP	p2=NN	60	nn	_
60	shares	share	NNS	_	58	pobj	_
61	on	on	IN	_	57	prep	_
62	16	0	CD	_	63	num	_
63	May	may	NNP	_	61	pobj	_
64	2014	0	CD	_	63	num	_
65	)	)	-RRB-	_	30	punct	_
66	(	(	-LRB-	_	30	punct	_
67	the	the	DT	_	70	det	_
68	"	"	``	_	70	punct	_
69	Friday	friday	NNP	_	70	nn	_
70	Proposal	proposal	NNP	_	30	appos	_
71	"	"	''	_	70	punct	_
72	)	)	-RRB-	_	30	punct	_
73	.	.	.	_	14	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	poss	_
2	's	's	POS	_	1	possessive	_
3	letter	letter	NN	_	6	nsubj	6:A0=PAG
4	did	do	VBD	_	6	aux	_
5	not	not	RB	_	6	neg	6:AM-NEG
6	provide	provide	VB	pb=provide.01	0	root	_
7	detail	detail	NN	_	6	dobj	6:A1=PPT
8	about	about	IN	_	6	prep	_
9	other	other	JJ	_	11	amod	_
10	key	key	JJ	_	11	amod	_
11	aspects	aspect	NNS	_	8	pobj	19:A1=PPT
12	of	of	IN	_	11	prep	_
13	its	its	PRP$	_	14	poss	_
14	proposal	proposal	NN	_	12	pobj	_
15	,	,	,	_	11	punct	_
16	several	several	JJ	_	19	nsubj	19:R-A1
17	of	of	IN	_	16	prep	_
18	which	which	WDT	_	17	pobj	_
19	are	be	VBP	pb=be.01	11	rcmod	_
20	of	of	IN	_	19	prep	19:A2=PRD
21	importance	importance	NN	_	20	pobj	_
22	to	to	IN	_	19	prep	_
23	the	the	DT	_	24	det	_
24	Board	board	NNP	_	26	poss	_
25	's	's	POS	_	24	possessive	_
26	evaluation	evaluation	NN	_	22	pobj	_
27	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	5	nsubj	5:A0=PAG;11:A0=PAG
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	3	pobj	_
5	met	meet	VBD	pb=meet.03	0	root	_
6	on	on	IN	_	5	prep	5:AM-TMP
7	17	0	CD	_	8	num	_
8	May	may	NNP	_	6	pobj	_
9	2014	0	CD	_	8	num	_
10	and	and	CC	_	5	cc	_
11	concluded	conclude	VBD	pb=conclude.01	5	conj	_
12	that	that	IN	_	21	complm	_
13	the	the	DT	_	15	det	_
14	financial	financial	JJ	_	15	amod	_
15	terms	term	NNS	_	21	nsubj	21:A0=PAG
16	of	of	IN	_	15	prep	_
17	the	the	DT	_	19	det	_
18	Friday	friday	NNP	_	19	nn	_
19	Proposal	proposal	NNP	_	16	pobj	_
20	substantially	substantially	RB	_	21	advmod	21:AM-MNR
21	undervalued	undervalue	VBD	pb=undervalue.01	11	ccomp	11:A1=PPT
22	the	the	DT	_	23	det	_
23	Company	company	NNP	p2=NN	21	dobj	21:A1=PPT
24	and	and	CC	_	23	cc	_
25	its	its	PRP$	_	27	poss	_
26	attractive	attractive	JJ	_	27	amod	_
27	prospects	prospect	NNS	_	23	conj	_
28	.	.	.	_	5	punct	_

1	Accordingly	accordingly	RB	_	7	advmod	7:AM-DIS
2	,	,	,	_	7	punct	_
3	the	the	DT	_	5	det	_
4	Friday	friday	NNP	_	5	nn	_
5	Proposal	proposal	NNP	p2=NN	7	nsubjpass	7:A1=PPT
6	was	be	VBD	_	7	auxpass	_
7	rejected	reject	VBN	pb=reject.01	0	root	_
8	.	.	.	_	7	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	3	nsubj	3:A0=PAG
3	wrote	write	VBD	pb=write.01	0	root	_
4	to	to	IN	_	3	prep	3:A2=GOL
5	Pfizer	pfizer	NNP	_	4	pobj	_
6	on	on	IN	_	3	prep	3:AM-TMP
7	the	the	DT	_	8	det	_
8	evening	evening	NN	_	6	pobj	_
9	of	of	IN	_	8	prep	_
10	17	0	CD	_	11	num	_
11	May	may	NNP	p2=MD	9	pobj	_
12	2014	0	CD	_	11	num	_
13	to	to	TO	_	14	aux	_
14	confirm	confirm	VB	pb=confirm.01	3	advcl	3:AM-PRP
15	that	that	IN	_	19	complm	_
16	the	the	DT	_	17	det	_
17	Board	board	NNP	_	19	nsubj	19:A0=PAG
18	had	have	VBD	_	19	aux	_
19	rejected	reject	VBN	pb=reject.01	14	ccomp	14:A1=PPT
20	the	the	DT	_	22	det	_
21	Friday	friday	NNP	_	22	nn	_
22	Proposal	proposal	NNP	p2=NN	19	dobj	19:A1=PPT
23	.	.	.	_	3	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	3	nsubj	3:A0=PAG;5:A0=PAG
3	offered	offer	VBD	pb=offer.01	0	root	_
4	to	to	TO	_	5	aux	_
5	hold	hold	VB	pb=hold.04	3	xcomp	3:A1=PPT
6	a	a	DT	_	7	det	_
7	meeting	meeting	NN	_	5	dobj	11:A0;5:A1=PPT
8	with	with	IN	_	7	prep	_
9	Pfizer	pfizer	NNP	_	8	pobj	_
10	to	to	TO	_	11	aux	_
11	explain	explain	VB	pb=explain.01	5	advcl	5:AM-PRP
12	its	its	PRP$	_	13	poss	_
13	views	view	NNS	_	11	dobj	11:A1=PPT
14	around	around	IN	_	13	prep	_
15	the	the	DT	_	17	det	_
16	substantial	substantial	JJ	_	17	amod	_
17	shortfall	shortfall	NN	_	14	pobj	_
18	in	in	IN	_	17	prep	_
19	value	value	NN	_	18	pobj	_
20	of	of	IN	_	19	prep	_
21	the	the	DT	_	23	det	_
22	Friday	friday	NNP	_	23	nn	_
23	Proposal	proposal	NNP	p2=NN	20	pobj	_
24	.	.	.	_	3	punct	_

1	·	·	NFP	p2=:	5	punct	_
2	The	the	DT	_	5	det	_
3	business	business	NN	_	5	nn	_
4	operating	operating	NN	p2=VBG	5	nn	_
5	model	model	NN	_	48	nn	10:A0;26:A0;28:A0
6	and	and	CC	_	5	cc	_
7	segmentation	segmentation	NN	_	5	conj	_
8	which	which	WDT	_	10	nsubj	10:R-A0
9	would	would	MD	_	10	aux	10:AM-MOD
10	allow	allow	VB	pb=allow.01	5	rcmod	_
11	AstraZeneca	astrazeneca	NNP	_	13	nsubj	13:A0=PAG
12	to	to	TO	_	13	aux	_
13	deliver	deliver	VB	pb=deliver.01	10	ccomp	10:A1=PPT
14	on	on	IN	_	13	prep	13:A1=PPT
15	its	its	PRP$	_	19	poss	_
16	research	research	NN	_	19	nn	_
17	and	and	CC	_	16	cc	_
18	development	development	NN	_	16	conj	_
19	pipeline	pipeline	NN	_	14	pobj	_
20	and	and	CC	_	19	cc	_
21	prospects	prospect	NNS	p2=VBZ	19	conj	_
22	;	;	:	p2=,	5	punct	_
23	and	and	CC	_	5	cc	_
24	which	which	WDT	_	26	nsubj	26:R-A0;28:R-A0
25	would	would	MD	_	26	aux	26:AM-MOD;28:AM-MOD
26	protect	protect	VB	pb=protect.01	5	rcmod	_
27	and	and	CC	_	26	cc	_
28	preserve	preserve	VB	pb=preserve.01	26	conj	_
29	its	its	PRP$	_	30	poss	_
30	culture	culture	NN	_	28	dobj	28:A1=PPT
31	of	of	IN	_	30	prep	_
32	science	science	NN	_	31	pobj	_
33	and	and	CC	_	32	cc	_
34	innovation	innovation	NN	_	32	conj	_
35	,	,	,	_	30	punct	_
36	especially	especially	RB	_	37	advmod	37:AM-ADV
37	given	give	VBN	pb=give.01	30	partmod	_
38	the	the	DT	_	39	det	_
39	likelihood	likelihood	NN	_	37	pobj	37:A1=PPT
40	of	of	IN	_	39	prep	_
41	material	material	NN	p2=JJ	42	nn	_
42	cost	cost	NN	p2=VBD	43	nn	_
43	savings	saving	NNS	_	81	nn	_
44	and	and	CC	_	43	cc	_
45	research	research	NN	_	48	nn	_
46	and	and	CC	_	45	cc	_
47	development	development	NN	_	45	conj	_
48	reductions	reduction	NNS	_	43	conj	_
49	;	;	:	p2=,	37	punct	_
50	·	·	NFP	p2=CC	75	punct	_
51	The	the	DT	_	52	det	_
52	details	detail	NNS	_	50	dobj	_
53	of	of	IN	_	52	prep	_
54	Pfizer	pfizer	NNP	p2=NN	56	poss	_
55	's	's	POS	_	54	possessive	_
56	plans	plan	NNS	_	53	pobj	_
57	for	for	IN	_	56	prep	_
58	cost	cost	NN	_	59	nn	_
59	savings	saving	NNS	_	57	pobj	_
60	,	,	,	_	59	punct	_
61	including	include	VBG	_	59	prep	_
62	around	around	IN	p2=CC	61	prep	_
63	research	research	NN	_	62	pobj	_
64	and	and	CC	_	63	cc	_
65	development	development	NN	_	63	conj	_
66	,	,	,	_	63	punct	_
67	pipeline	pipeline	NN	_	68	nn	_
68	delivery	delivery	NN	_	63	conj	_
69	and	and	CC	_	68	cc	_
70	employment	employment	NN	_	68	conj	_
71	;	;	:	p2=,	68	punct	_
72	·	·	NFP	p2=NNP	75	punct	_
73	Pfizer	pfizer	NNP	_	75	poss	_
74	's	's	POS	_	73	possessive	_
75	plans	plan	NNS	_	0	root	_
76	for	for	IN	_	75	prep	_
77	protecting	protect	VBG	pb=protect.01	76	pcomp	_
78	the	the	DT	_	79	det	_
79	certainty	certainty	NN	_	77	dobj	77:A1=PPT
80	of	of	IN	_	79	prep	_
81	delivery	delivery	NN	_	80	pobj	_
82	of	of	IN	_	81	prep	_
83	the	the	DT	_	84	det	_
84	value	value	NN	_	82	pobj	_
85	of	of	IN	_	84	prep	_
86	any	any	DT	_	87	det	_
87	offer	offer	NN	_	85	pobj	_
88	at	at	IN	_	87	prep	_
89	closing	closing	NN	_	88	pobj	_
90	.	.	.	_	75	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0=PAG
2	requested	request	VBD	pb=request.01	0	root	_
3	that	that	IN	_	7	complm	_
4	this	this	DT	_	5	det	_
5	meeting	meeting	NN	_	7	nsubjpass	7:A1=PPT
6	be	be	VB	_	7	auxpass	_
7	held	hold	VBN	pb=hold.04	2	ccomp	2:A1=PPT
8	by	by	IN	_	7	prep	7:A0=PAG
9	conference	conference	NN	_	10	nn	_
10	call	call	NN	_	8	pobj	_
11	.	.	.	_	2	punct	_

1	This	this	DT	_	3	det	_
2	conference	conference	NN	_	3	nn	_
3	call	call	NN	_	48	nsubj	48:A1=PPT
4	,	,	,	_	3	punct	_
5	between	between	IN	_	3	prep	_
6	Leif	leif	NNP	_	7	nn	_
7	Johansson	johansson	NNP	_	5	pobj	_
8	(	(	-LRB-	_	7	punct	_
9	Chairman	chairman	NNP	_	7	appos	_
10	)	)	-RRB-	_	7	punct	_
11	,	,	,	_	7	punct	_
12	Pascal	pascal	NNP	_	13	nn	_
13	Soriot	soriot	NNP	_	7	conj	_
14	(	(	-LRB-	_	13	punct	_
15	Chief	chief	NNP	_	17	nn	_
16	Executive	executive	NNP	_	17	nn	_
17	Officer	officer	NNP	_	13	appos	_
18	)	)	-RRB-	_	13	punct	_
19	and	and	CC	_	13	cc	_
20	Marc	marc	NNP	_	21	nn	_
21	Dunoyer	dunoyer	NNP	_	13	conj	_
22	(	(	-LRB-	_	21	punct	_
23	Chief	chief	NNP	_	25	nn	_
24	Financial	financial	NNP	_	25	nn	_
25	Officer	officer	NNP	_	21	appos	_
26	)	)	-RRB-	_	21	punct	_
27	of	of	IN	_	13	prep	_
28	AstraZeneca	astrazeneca	NNP	_	27	pobj	_
29	and	and	CC	_	28	cc	_
30	Ian	ian	NNP	_	31	nn	_
31	Read	read	NNP	_	28	conj	_
32	(	(	-LRB-	_	31	punct	_
33	Chairman	chairman	NNP	_	31	appos	_
34	and	and	CC	_	33	cc	_
35	CEO	ceo	NNP	p2=NN	33	conj	_
36	)	)	-RRB-	_	31	punct	_
37	and	and	CC	_	13	cc	_
38	Frank	frank	NNP	_	39	nn	_
39	D'Amelio	d'amelio	NNP	_	13	conj	_
40	(	(	-LRB-	_	39	punct	_
41	Chief	chief	NNP	_	43	nn	_
42	Financial	financial	NNP	_	43	nn	_
43	Officer	officer	NNP	_	39	appos	_
44	)	)	-RRB-	_	39	punct	_
45	of	of	IN	_	39	prep	_
46	Pfizer	pfizer	NNP	_	45	pobj	_
47	,	,	,	_	48	punct	_
48	took	take	VBD	pb=take.14	0	root	_
49	place	place	NN	_	48	dobj	48:A2
50	on	on	IN	_	48	prep	48:AM-TMP
51	the	the	DT	_	52	det	_
52	afternoon	afternoon	NN	_	50	pobj	_
53	of	of	IN	_	52	prep	_
54	18	0	CD	_	55	num	_
55	May	may	NNP	_	53	pobj	_
56	2014	0	CD	_	55	num	_
57	.	.	.	_	48	punct	_

1	The	the	DT	_	2	det	_
2	Chairman	chairman	NNP	_	5	nsubj	5:A0
3	of	of	IN	_	2	prep	_
4	Pfizer	pfizer	NNP	_	3	pobj	_
5	said	say	VBD	pb=say.01	0	root	_
6	that	that	IN	_	9	complm	_
7	Pfizer	pfizer	NNP	_	9	nsubj	9:A0=PAG
8	could	could	MD	_	9	aux	9:AM-MOD
9	consider	consider	VB	pb=consider.01	5	ccomp	5:A1=PPT
10	only	only	RB	p2=JJ	12	advmod	_
11	minor	minor	JJ	_	12	amod	_
12	improvements	improvement	NNS	_	9	dobj	9:A1
13	to	to	IN	_	12	prep	_
14	the	the	DT	_	16	det	_
15	financial	financial	JJ	_	16	amod	_
16	terms	term	NNS	_	13	pobj	_
17	of	of	IN	_	16	prep	_
18	the	the	DT	_	20	det	_
19	Friday	friday	NNP	_	20	nn	_
20	Proposal	proposal	NNP	p2=NN	17	pobj	_
21	.	.	.	_	5	punct	_

1	The	the	DT	_	2	det	_
2	Chairman	chairman	NNP	_	5	nsubj	5:A0=PAG
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	3	pobj	_
5	responded	respond	VBD	pb=respond.01	0	root	_
6	that	that	IN	p2=DT	38	complm	_
7	,	,	,	_	38	punct	_
8	even	even	RB	_	19	advmod	_
9	if	if	IN	_	19	mark	_
10	the	the	DT	_	13	det	_
11	other	other	JJ	_	13	amod	_
12	key	key	JJ	p2=NN	13	amod	_
13	aspects	aspect	NNS	_	19	nsubj	19:A1=PPT
14	of	of	IN	_	13	prep	_
15	the	the	DT	_	17	det	_
16	Friday	friday	NNP	_	17	nn	_
17	Proposal	proposal	NNP	p2=NN	14	pobj	_
18	had	have	VBD	_	19	aux	_
19	been	be	VBN	pb=be.01	38	advcl	38:AM-ADV
20	satisfactory	satisfactory	JJ	_	19	acomp	19:A2=PRD
21	,	,	,	_	38	punct	_
22	the	the	DT	_	23	det	_
23	price	price	NN	_	38	nsubj	40:A1=PPT;31:AM-LOC
24	at	at	IN	_	31	prep	31:R-AM-LOC
25	which	which	WDT	_	24	pobj	_
26	the	the	DT	_	27	det	_
27	Board	board	NNP	_	31	nsubj	34:A0=PAG;31:A1=PPT
28	of	of	IN	_	27	prep	_
29	AstraZeneca	astrazeneca	NNP	_	28	pobj	_
30	would	would	MD	_	31	aux	31:AM-MOD
31	be	be	VB	pb=be.01	23	rcmod	_
32	prepared	prepared	JJ	p2=VBN	31	acomp	31:A2=PRD
33	to	to	TO	_	34	aux	_
34	provide	provide	VB	pb=provide.01	32	xcomp	_
35	a	a	DT	_	36	det	_
36	recommendation	recommendation	NN	_	34	dobj	34:A1=PPT
37	would	would	MD	_	38	aux	38:AM-MOD
38	have	have	VB	pb=have.02	5	ccomp	5:A2=PPT
39	to	to	TO	_	40	aux	_
40	be	be	VB	pb=be.01	38	xcomp	_
41	more	more	JJR	_	43	amod	_
42	than	than	IN	_	43	quantmod	_
43	10	0	CD	_	44	num	_
44	%	%	NN	_	40	attr	40:A2=PRD
45	above	above	IN	_	44	prep	_
46	the	the	DT	_	47	det	_
47	level	level	NN	_	45	pobj	48:A1
48	contained	contain	VBN	p2=VBD|pb=contain.01	47	partmod	_
49	in	in	IN	_	48	prep	48:A0
50	Pfizer	pfizer	NNP	_	53	poss	_
51	's	's	POS	_	50	possessive	_
52	Friday	friday	NNP	_	53	nn	_
53	Proposal	proposal	NNP	_	49	pobj	_
54	.	.	.	_	5	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0=PAG
2	stated	state	VBD	pb=state.01	0	root	_
3	that	that	IN	_	7	complm	_
4	its	its	PRP$	_	6	poss	_
5	Friday	friday	NNP	_	6	nn	_
6	Proposal	proposal	NNP	p2=NN	7	nsubj	7:A1=PPT;13:A1=PPT
7	was	be	VBD	pb=be.01	2	ccomp	2:A1=PPT
8	final	final	JJ	_	7	acomp	7:A2=PRD
9	and	and	CC	_	7	cc	_
10	would	would	MD	_	13	aux	13:AM-MOD
11	not	not	RB	_	13	neg	13:AM-NEG
12	be	be	VB	_	13	auxpass	_
13	amended	amend	VBN	pb=amend.01	7	conj	_
14	.	.	.	_	2	punct	_

1	As	as	IN	_	6	prep	6:AM-MNR
2	a	a	DT	_	3	det	_
3	consequence	consequence	NN	_	1	pobj	_
4	the	the	DT	_	5	det	_
5	discussion	discussion	NN	_	6	nsubj	6:A1
6	ended	ended	VBD	pb=end.01	0	root	_
7	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	5	nsubj	5:A0=PAG;15:A0
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	3	pobj	_
5	met	meet	VBD	pb=meet.03	0	root	_
6	on	on	IN	_	5	prep	5:AM-TMP
7	18	0	CD	_	8	num	_
8	May	may	NNP	_	6	pobj	_
9	2014	0	CD	_	8	num	_
10	after	after	IN	_	5	prep	5:AM-TMP
11	this	this	DT	_	13	det	_
12	telephone	telephone	NN	_	13	nn	_
13	discussion	discussion	NN	_	10	pobj	_
14	and	and	CC	_	5	cc	_
15	reconfirmed	reconfirm	VBD	p2=VB|pb=reconfirm.01	5	conj	_
16	its	its	PRP$	_	17	poss	_
17	rejection	rejection	NN	_	15	dobj	15:A1
18	of	of	IN	_	17	prep	_
19	Pfizer	pfizer	NNP	_	22	poss	_
20	's	's	POS	_	19	possessive	_
21	Friday	friday	NNP	_	22	nn	_
22	Proposal	proposal	NNP	_	18	pobj	_
23	.	.	.	_	5	punct	_

1	A	a	DT	_	3	det	_
2	few	few	JJ	_	3	amod	_
3	hours	hour	NNS	_	4	npadvmod	_
4	later	later	RB	p2=RBR	19	advmod	19:AM-TMP
5	,	,	,	_	19	punct	_
6	without	without	IN	_	19	prep	19:AM-ADV
7	prior	prior	JJ	p2=RB	8	amod	_
8	notice	notice	NN	_	6	pobj	_
9	to	to	IN	p2=TO	8	prep	_
10	AstraZeneca	astrazeneca	NNP	_	9	pobj	_
11	and	and	CC	_	10	cc	_
12	contrary	contrary	JJ	p2=RB	10	conj	_
13	to	to	IN	_	12	prep	_
14	its	its	PRP$	_	16	poss	_
15	previous	previous	JJ	_	16	amod	_
16	statement	statement	NN	_	13	pobj	_
17	,	,	,	_	19	punct	_
18	Pfizer	pfizer	NNP	_	19	nsubj	19:A0=PAG
19	announced	announce	VBD	pb=announce.01	0	root	_
20	its	its	PRP$	_	22	poss	_
21	Final	final	JJ	p2=NNP	22	amod	_
22	Proposal	proposal	NN	p2=NNP	19	dobj	19:A1=PPT
23	to	to	IN	_	19	prep	19:A2=GOL
24	the	the	DT	_	25	det	_
25	market	market	NN	_	23	pobj	_
26	.	.	.	_	19	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	5	nsubj	5:A0=PAG;8:A0=PAG
3	of	of	IN	_	2	prep	_
4	AstraZeneca	astrazeneca	NNP	_	3	pobj	_
5	met	meet	VBD	pb=meet.01	0	root	_
6	again	again	RB	_	5	advmod	5:AM-TMP
7	and	and	CC	_	5	cc	_
8	rejected	reject	VBD	p2=VBN|pb=reject.01	5	conj	_
9	Pfizer	pfizer	NNP	_	12	poss	_
10	's	's	POS	_	9	possessive	_
11	Final	final	JJ	_	12	amod	_
12	Proposal	proposal	NN	p2=NNP	8	dobj	8:A1=PPT
13	for	for	IN	_	12	prep	_
14	reasons	reason	NNS	_	13	pobj	15:A1=PPT
15	set	set	VBD	p2=VBN|pb=set.07	14	partmod	_
16	out	out	RP	p2=RB	15	prt	15:C-V
17	below	below	RB	p2=IN	15	advmod	15:AM-LOC
18	.	.	.	_	5	punct	_

1	·	·	NFP	p2=POS	78	punct	_
2	AstraZeneca	astrazeneca	NNP	_	3	nsubj	3:A0=PAG;7:A0=PAG
3	has	have	VBZ	pb=have.03	78	ccomp	_
4	a	a	DT	_	5	det	_
5	growing	grow	VBG	p2=NN|pb=grow.01	51	advcl	_
6	and	and	CC	_	5	cc	_
7	accelerating	accelerate	VBG	pb=accelerate.01	5	conj	_
8	late	late	JJ	_	9	amod	_
9	stage	stage	NN	_	10	nn	_
10	pipeline	pipeline	NN	_	7	dobj	7:A1=PPT
11	,	,	,	_	5	punct	_
12	with	with	IN	_	58	prep	_
13	aggregate	aggregate	JJ	_	21	amod	_
14	risk	risk	NN	_	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	adjusted	adjust	VBN	_	18	amod	_
17	pipeline	pipeline	NN	_	18	nn	_
18	peak	peak	NN	_	21	nn	_
19	year	year	NN	_	21	nn	_
20	sales	sale	NNS	_	21	nn	_
21	potential	potential	NN	p2=JJ	12	pobj	_
22	of	of	IN	_	21	prep	_
23	around	around	RB	p2=IN	26	advmod	_
24	$	$	$	_	26	quantmod	_
25	23	0	CD	_	26	number	_
26	billion	#crd#	CD	_	22	pobj	_
27	and	and	CC	_	26	cc	_
28	non	non	AFX	p2=CD	31	advmod	_
29	risk	risk	NN	_	31	hmod	_
30	-	-	HYPH	_	31	hyph	_
31	adjusted	adjust	VBN	_	33	amod	_
32	pipeline	pipeline	NN	_	33	nn	_
33	peak	peak	NN	_	34	nn	_
34	year	year	NN	_	36	nn	_
35	sales	sale	NNS	_	36	nn	_
36	potential	potential	NN	p2=JJ	26	conj	_
37	of	of	IN	_	26	prep	_
38	around	around	RB	p2=IN	41	advmod	_
39	$	$	$	_	41	quantmod	_
40	63	0	CD	_	41	number	_
41	billion	#crd#	CD	_	37	pobj	_
42	;	;	:	p2=,	58	punct	_
43	·	·	NFP	p2=CC	51	punct	_
44	AstraZeneca	astrazeneca	NNP	_	49	poss	_
45	's	's	POS	p2=VBZ	44	possessive	_
46	five	#crd#	CD	_	49	num	_
47	key	key	JJ	_	49	amod	_
48	growth	growth	NN	_	49	nn	_
49	platforms	platform	NNS	_	51	nsubj	51:A0=PAG
50	are	be	VBP	_	51	aux	_
51	sustaining	sustain	VBG	pb=sustain.01	58	advcl	58:AM-ADV
52	near	near	JJ	p2=IN	54	hmod	_
53	-	-	HYPH	_	54	hyph	_
54	term	term	NN	_	55	nn	_
55	growth	growth	NN	_	51	dobj	51:A1=PPT
56	,	,	,	_	58	punct	_
57	AstraZeneca	astrazeneca	NNP	_	58	nsubj	58:A1=PPT
58	remains	remain	VBZ	pb=remain.01	3	ccomp	_
59	confident	confident	JJ	_	58	acomp	58:A3=PRD
60	that	that	IN	_	64	complm	_
61	2017	0	CD	_	62	num	_
62	revenues	revenue	NNS	_	64	nsubj	64:A1=PPT
63	should	should	MD	_	64	aux	64:AM-MOD
64	be	be	VB	pb=be.01	59	ccomp	_
65	broadly	broadly	RB	_	64	advmod	64:A2=PRD
66	in	in	IN	_	64	prep	_
67	line	line	NN	_	66	pobj	_
68	with	with	IN	_	67	prep	_
69	2013	0	CD	_	68	pobj	_
70	;	;	:	p2=,	78	punct	_
71	·	·	NFP	p2=JJS	78	punct	_
72	AstraZeneca	astrazeneca	NNP	_	76	poss	_
73	's	's	POS	_	72	possessive	_
74	core	core	NN	p2=JJ	76	nn	_
75	earnings	earnings	NNS	_	76	nn	_
76	growth	growth	NN	_	78	nsubjpass	78:A1=PPT;80:A1=PPT
77	is	be	VBZ	_	78	auxpass	_
78	expected	expect	VBN	pb=expect.01	0	root	_
79	to	to	TO	_	80	aux	_
80	be	be	VB	pb=be.01	78	xcomp	78:C-A1
81	in	in	IN	_	80	prep	80:A2=PRD
82	excess	excess	NN	_	81	pobj	_
83	of	of	IN	_	82	prep	_
84	revenue	revenue	NN	_	85	nn	_
85	growth	growth	NN	_	83	pobj	_
86	during	during	IN	_	80	prep	80:AM-TMP
87	the	the	DT	_	88	det	_
88	period	period	NN	_	86	pobj	_
89	from	from	IN	_	88	prep	_
90	2017	0	CD	_	89	pobj	_
91	to	to	IN	p2=TO	89	prep	_
92	2023	0	CD	_	91	pobj	_
93	as	as	IN	_	88	prep	_
94	a	a	DT	_	95	det	_
95	result	result	NN	_	93	pobj	_
96	of	of	IN	_	95	prep	_
97	operating	operate	VBG	p2=NN	98	nn	_
98	leverage	leverage	NN	_	96	pobj	_
99	.	.	.	_	78	punct	_

1	AstraZeneca	astrazeneca	NNP	p2=NN	2	nsubj	2:A0=PAG;4:A0
2	continues	continue	VBZ	pb=continue.01	0	root	_
3	to	to	TO	_	4	aux	_
4	demonstrate	demonstrate	VB	pb=demonstrate.01	2	xcomp	2:A1=PPT
5	strong	strong	JJ	_	6	amod	_
6	momentum	momentum	NN	_	4	dobj	4:A1=PPT
7	across	across	IN	_	4	prep	4:AM-DIR
8	all	all	DT	_	9	det	_
9	elements	element	NNS	_	7	pobj	_
10	of	of	IN	_	9	prep	_
11	its	its	PRP$	_	12	poss	_
12	strategy	strategy	NN	_	10	pobj	_
13	,	,	,	_	2	punct	_
14	as	as	IN	_	15	mark	_
15	evidenced	evidence	VBN	pb=evidence.01	2	advcl	_
16	by	by	IN	_	15	agent	15:A0=PAG
17	multiple	multiple	JJ	_	21	amod	_
18	recent	recent	JJ	_	21	amod	_
19	significant	significant	JJ	_	21	amod	_
20	pipeline	pipeline	NN	_	21	nn	_
21	developments	development	NNS	_	16	pobj	_
22	in	in	IN	_	21	prep	_
23	its	its	PRP$	_	26	poss	_
24	core	core	NN	_	25	nn	_
25	therapy	therapy	NN	_	26	nn	_
26	areas	area	NNS	_	22	pobj	_
27	.	.	.	_	2	punct	_

1	These	these	DT	_	3	det	_
2	pipeline	pipeline	NN	_	3	nn	_
3	developments	development	NNS	_	19	nsubj	19:A0=PAG;5:A1=PPT
4	,	,	,	_	3	punct	_
5	announced	announce	VBN	p2=VBD|pb=announce.01	3	partmod	_
6	in	in	IN	_	5	prep	5:AM-TMP
7	2014	0	CD	_	6	pobj	_
8	after	after	IN	_	5	prep	5:AM-TMP
9	completion	completion	NN	_	8	pobj	_
10	of	of	IN	_	9	prep	_
11	the	the	DT	_	12	det	_
12	Company	company	NNP	_	17	poss	_
13	's	's	POS	_	12	possessive	_
14	2013	0	CD	_	17	num	_
15	Long	long	NNP	_	17	nn	_
16	Range	range	NNP	_	17	nn	_
17	Plan	plan	NNP	_	10	pobj	_
18	,	,	,	_	19	punct	_
19	underpin	underpin	VB	p2=VBP|pb=underpin.01	0	root	_
20	the	the	DT	_	21	det	_
21	Board	board	NNP	_	23	poss	_
22	's	's	POS	_	21	possessive	_
23	confidence	confidence	NN	_	19	dobj	19:A1=PPT
24	in	in	IN	_	23	prep	_
25	AstraZeneca	astrazeneca	NNP	_	28	poss	_
26	's	's	POS	_	25	possessive	_
27	revenue	revenue	NN	_	28	nn	_
28	targets	target	NNS	_	24	pobj	_
29	due	due	JJ	_	28	amod	_
30	to	to	IN	_	29	prep	_
31	increased	increase	VBN	p2=VBD|pb=increase.01	32	amod	_
32	probabilities	probability	NNS	_	30	pobj	31:A1=PPT
33	of	of	IN	_	32	prep	_
34	success	success	NN	_	33	pobj	_
35	for	for	IN	_	34	prep	_
36	key	key	JJ	p2=NN	37	amod	_
37	oncology	oncology	NN	_	35	pobj	_
38	and	and	CC	_	37	cc	_
39	other	other	JJ	_	43	amod	_
40	specialty	specialty	NN	_	43	nn	_
41	franchise	franchise	NN	_	42	nn	_
42	pipeline	pipeline	NN	_	43	nn	_
43	assets	asset	NNS	_	37	conj	_
44	.	.	.	_	19	punct	_

1	As	as	IN	_	9	prep	9:AM-CAU
2	a	a	DT	_	3	det	_
3	result	result	NN	_	1	pobj	_
4	,	,	,	_	9	punct	_
5	AstraZeneca	astrazeneca	NNP	_	7	poss	_
6	's	's	POS	_	5	possessive	_
7	margins	margin	NNS	_	9	nsubjpass	9:A1=PPT;11:A1=PPT
8	are	be	VBP	_	9	auxpass	_
9	expected	expect	VBN	pb=expect.01	0	root	_
10	to	to	TO	_	11	aux	_
11	benefit	benefit	VB	pb=benefit.01	9	xcomp	9:C-A1
12	from	from	IN	_	11	prep	11:A0=PAG
13	this	this	DT	_	16	det	_
14	improved	improved	JJ	p2=VBN	16	amod	_
15	revenue	revenue	NN	_	16	nn	_
16	mix	mix	NN	_	12	pobj	_
17	.	.	.	_	9	punct	_

1	Given	give	VBN	_	13	prep	13:AM-ADV
2	that	that	IN	p2=DT	4	mark	_
3	AstraZeneca	astrazeneca	NNP	_	4	nsubj	4:A1=PPT
4	is	be	VBZ	pb=be.01	1	pcomp	_
5	at	at	IN	_	4	prep	4:A2=PRD
6	a	a	DT	_	7	det	_
7	point	point	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	inflection	inflection	NN	_	8	pobj	_
10	,	,	,	_	13	punct	_
11	the	the	DT	_	12	det	_
12	Board	board	NNP	_	13	nsubj	13:A0=PAG
13	believes	believe	VBZ	pb=believe.01	0	root	_
14	that	that	IN	_	25	complm	_
15	selling	sell	VBG	pb=sell.01	25	csubj	25:A0=PAG
16	AstraZeneca	astrazeneca	NNP	_	15	dobj	15:A1=PPT
17	at	at	IN	_	15	prep	15:A3=VSP
18	the	the	DT	_	20	det	_
19	final	final	JJ	_	20	amod	_
20	price	price	NN	_	17	pobj	21:A1=PPT
21	proposed	propose	VBN	pb=propose.01	20	partmod	_
22	by	by	IN	_	21	agent	21:A0=PAG
23	Pfizer	pfizer	NNP	_	22	pobj	_
24	would	would	MD	_	25	aux	25:AM-MOD
25	deprive	deprive	VB	pb=deprive.01	13	ccomp	13:A1=PPT
26	shareholders	shareholder	NNS	_	25	dobj	25:A2=DIR
27	of	of	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	value	value	NN	_	27	pobj	_
30	from	from	IN	_	25	prep	25:A1=PPT
31	potential	potential	JJ	_	34	amod	_
32	future	future	JJ	p2=NN	34	amod	_
33	pipeline	pipeline	NN	_	34	nn	_
34	success	success	NN	_	30	pobj	_
35	.	.	.	_	13	punct	_

1	Accordingly	accordingly	RB	_	5	advmod	5:AM-DIS
2	,	,	,	_	5	punct	_
3	the	the	DT	_	4	det	_
4	Board	board	NNP	_	5	nsubj	5:A0=PAG
5	believes	believe	VBZ	pb=believe.01	0	root	_
6	short	short	JJ	_	7	amod	_
7	term	term	NN	_	8	nn	_
8	metrics	metrics	NNS	p2=NN	27	nsubj	27:A1=PPT
9	,	,	,	_	8	punct	_
10	including	include	VBG	_	8	prep	_
11	premia	premia	NN	p2=NNS	10	pobj	_
12	over	over	IN	_	11	prep	_
13	historical	historical	JJ	_	15	amod	_
14	share	share	NN	_	15	nn	_
15	prices	price	NNS	_	12	pobj	_
16	,	,	,	_	8	punct	_
17	as	as	IN	_	18	mark	_
18	referenced	reference	VBN	pb=reference.01	8	advcl	_
19	by	by	IN	_	18	agent	18:A0=PAG
20	Pfizer	pfizer	NNP	_	19	pobj	_
21	regarding	regard	VBG	_	18	prep	_
22	the	the	DT	_	23	det	_
23	attractiveness	attractiveness	NN	_	21	pobj	_
24	of	of	IN	_	23	prep	_
25	its	its	PRP$	_	26	poss	_
26	proposals	proposal	NNS	_	24	pobj	_
27	are	be	VBP	pb=be.01	5	ccomp	5:A1=PPT
28	not	not	RB	_	27	neg	27:AM-NEG
29	appropriate	appropriate	JJ	_	30	amod	_
30	bases	base	NNS	_	27	attr	27:A2=PRD
31	for	for	IN	_	30	prep	_
32	assessing	assess	VBG	pb=assess.01	31	pcomp	_
33	the	the	DT	_	34	det	_
34	value	value	NN	_	32	dobj	32:A1=PPT
35	of	of	IN	_	34	prep	_
36	AstraZeneca	astrazeneca	NNP	_	35	pobj	_
37	.	.	.	_	5	punct	_

1	The	the	DT	_	2	det	_
2	majority	majority	NN	_	6	nsubj	6:A1=PPT
3	of	of	IN	_	2	prep	_
4	the	the	DT	_	5	det	_
5	consideration	consideration	NN	_	3	pobj	_
6	is	be	VBZ	pb=be.01	0	root	_
7	in	in	IN	_	6	prep	6:A2=PRD
8	Pfizer	pfizer	NNP	_	9	nn	_
9	shares	share	NNS	_	7	pobj	18:A1=PPT
10	which	which	WDT	_	18	dobj	18:R-A1
11	many	many	JJ	_	13	amod	_
12	AstraZeneca	astrazeneca	NNP	p2=JJ	13	nn	_
13	shareholders	shareholder	NNS	_	16	nsubjpass	18:A0=PAG;16:A1=PPT
14	will	will	MD	_	16	aux	16:AM-MOD
15	be	be	VB	_	16	auxpass	_
16	forced	force	VBN	pb=force.01	9	rcmod	_
17	to	to	TO	_	18	aux	_
18	sell	sell	VB	pb=sell.01	16	xcomp	16:A2=PRD
19	.	.	.	_	6	punct	_

1	Further	far	RB	_	15	advmod	15:AM-DIS
2	,	,	,	_	15	punct	_
3	for	for	IN	_	15	prep	15:AM-ADV
4	those	those	DT	_	6	det	_
5	AstraZeneca	astrazeneca	NNP	p2=JJ	6	nn	_
6	shareholders	shareholder	NNS	_	3	pobj	9:A0=PAG
7	able	able	JJ	_	6	amod	_
8	to	to	TO	_	9	aux	_
9	hold	hold	VB	pb=hold.01	7	xcomp	_
10	Pfizer	pfizer	NNP	p2=NN	11	nn	_
11	shares	share	NNS	_	9	dobj	9:A1=PPT
12	,	,	,	_	15	punct	_
13	the	the	DT	_	14	det	_
14	Board	board	NNP	_	15	nsubj	15:A0=PAG
15	believes	believe	VBZ	pb=believe.01	0	root	_
16	Pfizer	pfizer	NNP	_	18	poss	_
17	's	's	POS	_	16	possessive	_
18	proposals	proposal	NNS	_	21	nsubj	21:A0=PAG;26:A0=PAG
19	would	would	MD	_	21	aux	21:AM-MOD;26:AM-MOD
20	materially	materially	RB	_	21	advmod	21:AM-MNR
21	alter	alter	VB	pb=alter.01	15	ccomp	15:A1=PPT
22	the	the	DT	_	24	det	_
23	investment	investment	NN	_	24	nn	_
24	case	case	NN	_	21	dobj	21:A1=PPT
25	and	and	CC	_	21	cc	_
26	create	create	VB	p2=VBP|pb=create.01	21	conj	_
27	risks	risk	NNS	_	26	dobj	26:A1=PPT
28	and	and	CC	_	27	cc	_
29	uncertainties	uncertainty	NNS	_	27	conj	_
30	.	.	.	_	15	punct	_

1	·	·	NFP	p2=NNP	6	punct	_
2	Pfizer	pfizer	NNP	_	4	poss	_
3	's	's	POS	_	2	possessive	_
4	proposals	proposal	NNS	_	6	nsubjpass	15:A0=CAU;6:A1=PPT
5	are	be	VBP	_	6	auxpass	_
6	predicated	predicate	VBN	p2=JJ|pb=predicate.01	32	ccomp	_
7	on	on	IN	_	6	prep	6:A2
8	the	the	DT	_	9	det	_
9	delivery	delivery	NN	_	7	pobj	_
10	of	of	IN	_	9	prep	_
11	significant	significant	JJ	_	13	amod	_
12	cost	cost	NN	_	13	nn	_
13	reductions	reduction	NNS	_	10	pobj	_
14	and	and	CC	_	6	cc	_
15	imply	imply	VB	p2=VBP|pb=imply.01	6	conj	_
16	a	a	DT	_	18	det	_
17	meaningful	meaningful	JJ	_	18	amod	_
18	reduction	reduction	NN	_	15	dobj	15:A1=PPT
19	in	in	IN	_	18	prep	_
20	research	research	NN	_	19	pobj	_
21	and	and	CC	_	20	cc	_
22	development	development	NN	_	20	conj	_
23	potential	potential	NN	p2=JJ	20	conj	_
24	and	and	CC	_	23	cc	_
25	capabilities	capability	NNS	_	23	conj	_
26	;	;	:	p2=,	32	punct	_
27	·	·	NFP	p2=CC	32	punct	_
28	The	the	DT	_	30	det	_
29	associated	associate	VBN	p2=JJ|pb=associate.01	30	amod	_
30	integration	integration	NN	_	32	nsubj	32:A0=PAG;29:A1=PPT
31	would	would	MD	_	32	aux	32:AM-MOD
32	risk	risk	VB	pb=risk.01	0	root	_
33	significant	significant	JJ	_	34	amod	_
34	disruption	disruption	NN	_	32	dobj	32:A1=PPT
35	to	to	IN	_	32	prep	32:AM-ADV
36	the	the	DT	_	37	det	_
37	delivery	delivery	NN	_	35	pobj	_
38	and	and	CC	_	37	cc	_
39	value	value	NN	_	37	conj	_
40	of	of	IN	_	37	prep	_
41	AstraZeneca	astrazeneca	NNP	_	43	poss	_
42	's	's	POS	_	41	possessive	_
43	pipeline	pipeline	NN	_	40	pobj	_
44	;	;	:	p2=,	32	punct	_
45	·	·	NFP	p2=NNP	50	punct	_
46	Pfizer	pfizer	NNP	_	50	poss	_
47	's	's	POS	_	46	possessive	_
48	announced	announce	VBN	p2=JJ|pb=announce.01	50	amod	_
49	business	business	NN	_	50	nn	_
50	segmentation	segmentation	NN	_	63	nsubj	63:A0=PAG;48:A1=PPT
51	,	,	,	_	63	punct	_
52	if	if	IN	_	55	mark	_
53	it	it	PRP	_	55	nsubjpass	55:A1=PPT
54	were	be	VBD	_	55	auxpass	_
55	applied	apply	VBN	pb=apply.02	63	advcl	63:AM-ADV
56	to	to	IN	_	55	prep	55:A2=PRD
57	AstraZeneca	astrazeneca	NNP	_	59	poss	_
58	's	's	POS	_	57	possessive	_
59	business	business	NN	_	56	pobj	_
60	,	,	,	_	63	punct	_
61	would	would	MD	_	63	aux	63:AM-MOD
62	likely	likely	RB	_	63	advmod	63:AM-ADV
63	lead	lead	VB	pb=lead.03	32	conj	_
64	to	to	IN	_	63	prep	63:A2=PRD
65	value	value	NN	_	66	nn	_
66	destruction	destruction	NN	_	64	pobj	_
67	.	.	.	_	63	punct	_

1	In	in	IN	_	9	prep	9:AM-LOC
2	the	the	DT	_	3	det	_
3	context	context	NN	_	1	pobj	_
4	of	of	IN	_	3	prep	_
5	the	the	DT	_	6	det	_
6	above	above	JJ	p2=RB	4	pobj	_
7	,	,	,	_	9	punct	_
8	AstraZeneca	astrazeneca	NNP	_	9	nsubj	9:A0=PAG
9	notes	note	VBZ	pb=note.01	0	root	_
10	the	the	DT	_	12	det	_
11	recent	recent	JJ	_	12	amod	_
12	decline	decline	NN	_	9	dobj	9:A1=PPT
13	in	in	IN	_	12	prep	_
14	Pfizer	pfizer	NNP	_	17	poss	_
15	's	's	POS	_	14	possessive	_
16	share	share	NN	_	17	nn	_
17	price	price	NN	_	13	pobj	21:A1=PPT
18	,	,	,	_	17	punct	_
19	which	which	WDT	_	21	nsubj	21:R-A1
20	has	have	VBZ	_	21	aux	_
21	fallen	fall	VBN	pb=fall.01	17	rcmod	_
22	by	by	IN	_	21	prep	21:A4=GOL
23	5.3	0	CD	_	24	num	_
24	%	%	NN	_	22	pobj	_
25	since	since	IN	_	21	prep	21:AM-TMP
26	the	the	DT	_	27	det	_
27	release	release	NN	_	25	pobj	_
28	of	of	IN	_	27	prep	_
29	Pfizer	pfizer	NNP	_	33	poss	_
30	's	's	POS	_	29	possessive	_
31	Q1	q1	NNP	p2=CD	33	nn	_
32	2014	0	CD	_	31	num	_
33	results	result	NNS	_	28	pobj	_
34	.	.	.	_	9	punct	_

1	The	the	DT	_	6	det	_
2	tax	tax	NN	_	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	driven	drive	VBN	p2=JJ	6	amod	_
5	inversion	inversion	NN	_	6	nn	_
6	structure	structure	NN	_	7	nsubj	7:A1=PPT
7	remains	remain	VBZ	pb=remain.01	0	root	_
8	a	a	DT	_	10	det	_
9	key	key	JJ	_	10	amod	_
10	part	part	NN	_	7	attr	7:A3=PRD
11	of	of	IN	_	10	prep	_
12	Pfizer	pfizer	NNP	_	14	poss	_
13	's	's	POS	_	12	possessive	_
14	proposals	proposal	NNS	_	11	pobj	_
15	.	.	.	_	7	punct	_

1	The	the	DT	_	3	det	_
2	inversion	inversion	NN	p2=JJ	3	nn	_
3	structure	structure	NN	_	6	nsubj	6:A1=PPT
4	has	have	VBZ	_	6	aux	_
5	already	already	RB	_	6	advmod	6:AM-TMP
6	been	be	VBN	pb=be.01	0	root	_
7	the	the	DT	_	8	det	_
8	subject	subject	NN	_	6	attr	6:A2=PRD
9	of	of	IN	_	8	prep	_
10	intense	intense	JJ	_	14	amod	_
11	public	public	JJ	p2=NN	14	amod	_
12	and	and	CC	_	11	cc	_
13	governmental	governmental	JJ	_	11	conj	_
14	scrutiny	scrutiny	NN	_	9	pobj	_
15	,	,	,	_	6	punct	_
16	particularly	particularly	RB	_	17	advmod	_
17	in	in	IN	_	6	prep	_
18	the	the	DT	_	19	det	_
19	US	us	NNP	_	17	pobj	_
20	,	,	,	_	6	punct	_
21	as	as	IN	_	6	prep	6:AM-CAU
22	a	a	DT	_	23	det	_
23	result	result	NN	_	21	pobj	_
24	of	of	IN	_	23	prep	_
25	Pfizer	pfizer	NNP	p2=NN	28	poss	_
26	's	's	POS	_	25	possessive	_
27	possible	possible	JJ	_	28	amod	_
28	offer	offer	NN	_	24	pobj	_
29	for	for	IN	_	28	prep	_
30	AstraZeneca	astrazeneca	NNP	_	29	pobj	_
31	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	3	nsubj	3:A0=PAG
3	believes	believe	VBZ	pb=believe.01	0	root	_
4	this	this	DT	_	5	det	_
5	structure	structure	NN	_	6	nsubj	6:A0=PAG
6	brings	bring	VBZ	pb=bring.01	3	ccomp	3:A1=PPT
7	increased	increase	VBN	pb=increase.01	8	amod	_
8	uncertainty	uncertainty	NN	_	6	dobj	6:A1=PPT;7:A1=PPT
9	as	as	IN	_	10	mark	_
10	regards	regard	VBZ	p2=NNS|pb=regard.01	6	advcl	6:AM-ADV
11	the	the	DT	_	12	det	_
12	delivery	delivery	NN	_	10	dobj	10:A1
13	of	of	IN	_	12	prep	_
14	value	value	NN	_	13	pobj	_
15	for	for	IN	_	14	prep	_
16	AstraZeneca	astrazeneca	NNP	_	17	nn	_
17	shareholders	shareholder	NNS	_	15	pobj	_
18	.	.	.	_	3	punct	_

1	The	the	DT	_	2	det	_
2	Board	board	NNP	_	3	nsubj	3:A0=PAG
3	believes	believe	VBZ	pb=believe.01	0	root	_
4	that	that	IN	_	34	complm	_
5	Pfizer	pfizer	NNP	_	8	poss	_
6	's	's	POS	_	5	possessive	_
7	Final	final	JJ	p2=NNP	8	amod	_
8	Proposal	proposal	NNP	p2=NN	34	nsubj	34:A1=PPT
9	,	,	,	_	8	punct	_
10	in	in	IN	_	8	prep	_
11	relation	relation	NN	_	10	pobj	_
12	to	to	IN	p2=TO	11	prep	_
13	price	price	NN	_	12	pobj	_
14	,	,	,	_	8	punct	_
15	form	form	NN	_	8	appos	_
16	of	of	IN	_	15	prep	_
17	consideration	consideration	NN	_	16	pobj	_
18	and	and	CC	_	15	cc	_
19	the	the	DT	_	22	det	_
20	four	#crd#	CD	_	22	num	_
21	particular	particular	JJ	_	22	amod	_
22	points	point	NNS	_	15	conj	24:A1=PPT
23	that	that	WDT	_	24	nsubj	24:R-A1
24	are	be	VBP	pb=be.01	22	rcmod	_
25	central	central	JJ	_	24	acomp	24:A2=PRD
26	to	to	IN	_	25	prep	_
27	the	the	DT	_	28	det	_
28	Board	board	NNP	_	30	poss	_
29	's	's	POS	_	28	possessive	_
30	concerns	concern	NNS	_	26	pobj	_
31	around	around	IN	_	30	prep	_
32	value	value	NN	_	31	pobj	_
33	,	,	,	_	34	punct	_
34	remains	remain	VBZ	pb=remain.01	3	ccomp	3:A1=PPT
35	inadequate	inadequate	JJ	_	34	acomp	34:A3=PRD
36	.	.	.	_	3	punct	_

1	Accordingly	accordingly	RB	_	6	advmod	6:AM-DIS
2	,	,	,	_	6	punct	_
3	the	the	DT	_	4	det	_
4	Board	board	NNP	_	6	nsubj	6:A0=PAG
5	has	have	VBZ	_	6	aux	_
6	rejected	reject	VBN	pb=reject.01	0	root	_
7	the	the	DT	_	9	det	_
8	Final	final	JJ	p2=NNP	9	amod	_
9	Proposal	proposal	NNP	p2=NN	6	dobj	6:A1=PPT
10	.	.	.	_	6	punct	_

1	This	this	DT	_	2	det	_
2	statement	statement	NN	_	5	nsubjpass	5:A1
3	is	be	VBZ	_	5	aux	_
4	being	be	VBG	_	5	auxpass	_
5	made	make	VBN	pb=make.LV	0	root	_
6	by	by	IN	_	5	agent	5:A0
7	AstraZeneca	astrazeneca	NNP	_	6	pobj	_
8	without	without	IN	_	5	prep	5:AM-MNR
9	prior	prior	JJ	p2=JJR	10	amod	_
10	agreement	agreement	NN	_	8	pobj	_
11	or	or	CC	_	10	cc	_
12	approval	approval	NN	_	10	conj	_
13	of	of	IN	_	12	prep	_
14	Pfizer	pfizer	NNP	_	13	pobj	_
15	.	.	.	_	5	punct	_

1	It	it	PRP	_	2	nsubj	2:A1=PPT
2	's	be	VBZ	pb=be.01	0	root	_
3	more	more	JJR	_	2	attr	2:A2=PRD
4	of	of	IN	_	3	prep	_
5	a	a	DT	_	6	det	_
6	proposal	proposal	NN	_	4	pobj	_
7	than	than	IN	_	3	prep	_
8	a	a	DT	_	9	det	_
9	bid	bid	NN	_	7	pobj	_
10	,	,	,	_	2	punct	_
11	really	really	RB	_	2	advmod	2:AM-ADV
12	.	.	.	_	2	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	nsubj	3:A0=PAG
2	has	have	VBZ	_	3	aux	_
3	made	make	VBN	pb=make.02	0	root	_
4	it	it	PRP	_	5	nsubj	_
5	clear	clear	JJ	_	3	ccomp	3:A1=PRD
6	it	it	PRP	_	7	nsubj	7:A0=PAG;9:A0=PAG
7	wants	want	VBZ	pb=want.01	5	advcl	_
8	to	to	TO	_	9	aux	_
9	buy	buy	VB	pb=buy.01	7	xcomp	7:A1=PPT
10	British	british	NNP	p2=JJ	12	hmod	_
11	-	-	HYPH	_	12	hyph	_
12	based	base	VBN	_	13	amod	_
13	AstraZeneca	astrazeneca	NNP	_	9	dobj	9:A1=PPT
14	and	and	CC	_	9	cc	_
15	that	that	IN	_	18	mark	_
16	it	it	PRP	_	18	nsubj	18:A0=PAG
17	will	will	MD	_	18	aux	18:AM-MOD
18	pay	pay	VB	pb=pay.01	9	conj	_
19	£63bn	£0bn	RP	p2=CD	18	prt	18:C-V
20	for	for	IN	_	18	prep	18:A3=PPT
21	it	it	PRP	_	20	pobj	_
22	but	but	CC	_	3	cc	_
23	there	there	EX	_	24	expl	_
24	's	be	VBZ	pb=be.02	3	conj	_
25	no	no	DT	_	27	det	_
26	official	official	JJ	p2=NN	27	amod	_
27	bid	bid	NN	_	24	attr	24:A1=PPT
28	.	.	.	_	24	punct	_

1	AstraZeneca	astrazeneca	NNP	_	3	nsubj	3:A0=PAG
2	has	have	VBZ	_	3	aux	_
3	made	make	VBN	pb=make.02	0	root	_
4	it	it	PRP	_	5	nsubj	_
5	plain	plain	JJ	p2=IN	3	ccomp	3:A1=PRD
6	it	it	PRP	_	7	nsubj	7:A1=PPT
7	's	be	VBZ	pb=be.01	5	advcl	_
8	not	not	RB	_	7	neg	7:AM-NEG
9	interested	interested	JJ	_	7	acomp	7:A2=PRD
10	,	,	,	_	7	punct	_
11	at	at	IN	p2=RB	12	advmod	_
12	least	least	JJS	p2=RBS	14	advmod	_
13	not	not	RB	_	14	neg	_
14	for	for	IN	_	7	prep	7:AM-CAU
15	that	that	DT	_	16	det	_
16	amount	amount	NN	_	14	pobj	_
17	,	,	,	_	3	punct	_
18	and	and	CC	_	3	cc	_
19	the	the	DT	_	20	det	_
20	management	management	NN	_	24	nsubj	24:A0=PAG
21	have	have	VBP	_	24	aux	_
22	n't	not	RB	_	24	neg	24:AM-NEG
23	even	even	RB	_	24	advmod	24:AM-ADV
24	held	hold	VBN	pb=hold.04	3	conj	_
25	talks	talk	NNS	_	24	dobj	24:A1=PPT
26	.	.	.	_	24	punct	_

1	No.	no.	NN	p2=NFP	2	nn	_
2	Pfizer	pfizer	NNP	p2=NN	4	nsubj	4:A0=PAG;8:A0=PAG
3	can	can	MD	_	4	aux	4:AM-MOD;8:AM-MOD
4	raise	raise	VB	pb=raise.01	0	root	_
5	its	its	PRP$	_	6	poss	_
6	bid	bid	NN	_	4	dobj	4:A1=PPT
7	or	or	CC	_	4	cc	_
8	launch	launch	VB	p2=NN|pb=launch.01	4	conj	_
9	a	a	DT	_	12	det	_
10	hostile	hostile	JJ	_	12	amod	_
11	takeover	takeover	NN	_	12	nn	_
12	offer	offer	NN	_	8	dobj	8:A1=PPT;29:A1;16:AM-LOC
13	in	in	IN	_	16	prep	16:R-AM-LOC
14	which	which	WDT	_	13	pobj	_
15	it	it	PRP	_	16	nsubj	16:A0=PAG
16	appeals	appeal	VBZ	pb=appeal.03	12	rcmod	_
17	directly	directly	RB	_	16	advmod	16:AM-MNR
18	to	to	IN	_	16	prep	16:A1=PPT
19	AstraZeneca	astrazeneca	NNP	_	21	poss	_
20	's	's	POS	_	19	possessive	_
21	shareholders	shareholder	NNS	_	18	pobj	_
22	to	to	TO	_	23	aux	_
23	sell	sell	VB	pb=sell.01	16	xcomp	16:AM-PNC
24	up	up	RP	p2=RB	23	prt	23:C-V
25	-	-	:	p2=,	12	punct	_
26	which	which	WDT	_	29	dobj	29:R-A1
27	they	they	PRP	_	29	nsubj	29:A0=PAG
28	may	may	MD	_	29	aux	29:AM-MOD
29	do	do	VB	pb=do.02	12	rcmod	_
30	thinking	think	VBG	p2=NN|pb=think.01	8	advcl	8:AM-ADV
31	it	it	PRP	_	32	nsubj	32:A1=PPT
32	is	be	VBZ	pb=be.01	30	ccomp	30:A1=PPT
33	a	a	DT	_	35	det	_
34	better	good	JJR	_	35	amod	_
35	deal	deal	NN	_	32	attr	32:A2=PRD
36	.	.	.	_	4	punct	_

1	Kerching	kerching	VBG	p2=VBG|pb=kerching.01	0	root	_
2	.	.	.	_	1	punct	_

1	It	it	PRP	_	3	nsubjpass	_
2	's	's	VBZ	_	3	auxpass	_
3	made	make	VBN	pb=make.02	0	root	_
4	it	it	PRP	_	6	nsubj	_
5	pretty	pretty	RB	p2=JJ	6	advmod	_
6	clear	clear	JJ	_	3	ccomp	3:A1=PRD
7	that	that	IN	_	11	complm	_
8	buying	buy	VBG	p2=NN|pb=buy.01	11	csubj	11:A0=PAG
9	AstraZeneca	astrazeneca	NNP	_	8	dobj	8:A1=PPT
10	would	would	MD	_	11	aux	11:AM-MOD
11	allow	allow	VB	pb=allow.01	6	advcl	_
12	it	it	PRP	_	15	nsubjpass	15:A1
13	to	to	TO	_	15	aux	_
14	be	be	VB	_	15	auxpass	_
15	domiciled	domicile	VBN	pb=domicile.01	11	ccomp	11:A1=PPT
16	in	in	IN	_	15	prep	15:AM-LOC
17	the	the	DT	_	18	det	_
18	UK	uk	NNP	p2=NN	16	pobj	_
19	so	so	IN	p2=RB	22	mark	_
20	it	it	PRP	_	22	nsubj	22:A0=PAG
21	can	can	MD	_	22	aux	22:AM-MOD
22	pay	pay	VB	pb=pay.01	15	advcl	15:AM-PRP
23	tax	tax	NN	_	22	dobj	22:A1=VSP
24	to	to	IN	_	22	prep	22:A2=GOL
25	the	the	DT	_	27	det	_
26	British	british	JJ	p2=NNP	27	amod	_
27	Government	government	NNP	p2=NN	24	pobj	_
28	.	.	.	_	3	punct	_

1	Corporation	corporation	NN	p2=NNP	2	nn	_
2	tax	tax	NN	_	6	nsubj	6:A1=PPT
3	in	in	IN	_	2	prep	_
4	the	the	DT	_	5	det	_
5	UK	uk	NNP	_	3	pobj	_
6	is	be	VBZ	pb=be.01	0	root	_
7	20	0	CD	_	8	num	_
8	%	%	NN	_	6	attr	6:A2=PRD
9	from	from	IN	_	6	prep	_
10	next	next	JJ	_	11	amod	_
11	year	year	NN	_	9	pobj	_
12	but	but	CC	_	6	cc	_
13	in	in	IN	_	17	prep	17:AM-LOC
14	the	the	DT	_	16	det	_
15	US	us	NNP	_	16	nn	_
16	companies	company	NNS	_	17	nsubj	17:A0=PAG
17	pay	pay	VBP	pb=pay.01	6	conj	_
18	38	0	CD	_	19	num	_
19	%	%	NN	_	17	dobj	17:A1=VSP
20	of	of	IN	_	19	prep	_
21	profits	profit	NNS	_	20	pobj	_
22	in	in	IN	_	21	prep	_
23	similar	similar	JJ	_	24	amod	_
24	taxes	tax	NNS	_	22	pobj	_
25	.	.	.	_	17	punct	_

1	Uncertainty	uncertainty	NN	_	11	dep	_
2	and	and	CC	_	1	cc	_
3	potentially	potentially	RB	_	5	advmod	_
4	job	job	NN	p2=VB	5	nn	_
5	losses	loss	NNS	_	1	conj	_
6	-	-	:	p2=,	11	punct	_
7	Pfizer	pfizer	NNP	p2=NN	9	poss	_
8	's	's	POS	_	7	possessive	_
9	boss	boss	NN	_	11	nsubj	11:A0=PAG
10	has	have	VBZ	_	11	aux	_
11	admitted	admit	VBN	pb=admit.01	0	root	_
12	this	this	DT	_	11	dobj	11:A1
13	.	.	.	_	11	punct	_

1	There	there	EX	_	2	expl	_
2	are	be	VBP	pb=be.02	0	root	_
3	real	real	JJ	_	4	amod	_
4	fears	fear	NNS	_	2	attr	2:A1=PPT
5	Pfizer	pfizer	NNP	_	8	nsubj	8:A0=PAG;10:A0=PAG
6	will	will	MD	_	8	aux	8:AM-MOD
7	asset	asset	VB	p2=NN	8	aux	_
8	strip	strip	VB	pb=strip.01	4	ccomp	_
9	AstraZeneca	astrazeneca	NNP	_	8	dobj	8:A2=DIR
10	leading	lead	VBG	pb=lead.01	8	advcl	_
11	to	to	IN	_	10	prep	10:A4=GOL
12	significant	significant	JJ	_	13	amod	_
13	redundancies	redundancy	NNS	p2=NN	11	pobj	_
14	and	and	CC	_	13	cc	_
15	substantial	substantial	JJ	_	16	amod	_
16	damage	damage	NN	_	13	conj	_
17	to	to	IN	_	16	prep	_
18	British	british	JJ	_	21	amod	_
19	scientific	scientific	JJ	_	20	amod	_
20	research	research	NN	_	21	nn	_
21	capabilities	capability	NNS	_	17	pobj	_
22	.	.	.	_	2	punct	_

1	No	no	UH	_	5	intj	5:AM-DIS
2	,	,	,	_	5	punct	_
3	it	it	PRP	_	5	nsubj	5:A0
4	has	have	VBZ	_	5	aux	_
5	guaranteed	guarantee	VBN	pb=guarantee.01	0	root	_
6	it	it	PRP	_	8	nsubj	8:A0=PAG
7	will	will	MD	_	8	aux	8:AM-MOD
8	base	base	VB	pb=base.02	5	ccomp	5:A1=PPT
9	20	0	CD	_	10	num	_
10	%	%	NN	_	8	dobj	8:A1=PPT
11	of	of	IN	_	10	prep	_
12	its	its	PRP$	_	17	poss	_
13	worldwide	worldwide	JJ	_	17	amod	_
14	research	research	NN	_	17	nn	_
15	and	and	CC	_	14	cc	_
16	development	development	NN	_	14	conj	_
17	staff	staff	NN	_	11	pobj	_
18	in	in	IN	_	8	prep	8:AM-LOC
19	Britain	britain	NNP	_	18	pobj	_
20	-	-	:	p2=,	8	punct	_
21	not	not	RB	_	22	neg	_
22	quite	quite	PDT	p2=RB	25	predet	_
23	the	the	DT	_	25	det	_
24	same	same	JJ	_	25	amod	_
25	thing	thing	NN	_	8	dobj	_
26	.	.	.	_	5	punct	_

1	It	it	PRP	_	4	nsubj	4:A0
2	wo	wo	MD	_	4	aux	4:AM-MOD
3	n't	not	RB	_	4	neg	4:AM-NEG
4	say	say	VB	pb=say.01	0	root	_
5	how	how	WRB	_	6	advmod	_
6	many	many	JJ	_	7	amod	_
7	people	people	NNS	_	1	appos	_
8	or	or	CC	_	7	cc	_
9	where	where	WRB	_	16	advmod	16:R-AM-LOC
10	in	in	IN	_	16	prep	16:AM-LOC
11	the	the	DT	_	12	det	_
12	UK	uk	NNP	_	10	pobj	_
13	they	they	PRP	_	16	nsubjpass	16:A1=PPT
14	will	will	MD	_	16	aux	16:AM-MOD
15	be	be	VB	_	16	auxpass	_
16	based	base	VBN	pb=base.02	7	conj	_
17	,	,	,	_	16	punct	_
18	although	although	IN	_	21	mark	_
19	it	it	PRP	_	21	nsubj	21:A0
20	has	have	VBZ	_	21	aux	_
21	said	say	VBN	p2=VBD|pb=say.01	16	advcl	_
22	it	it	PRP	_	24	nsubj	24:A0=PAG
23	will	will	MD	_	24	aux	24:AM-MOD
24	keep	keep	VB	pb=keep.02	21	ccomp	21:A1=PPT
25	AstraZeneca	astrazeneca	NNP	_	30	poss	_
26	's	's	POS	_	25	possessive	_
27	new	new	JJ	_	30	amod	_
28	Cambridge	cambridge	NNP	_	30	nn	_
29	research	research	NN	_	30	nn	_
30	facility	facility	NN	_	24	dobj	24:A1=PPT
31	.	.	.	_	4	punct	_

1	In	in	IN	_	14	prep	14:AM-LOC
2	a	a	DT	_	3	det	_
3	way	way	NN	_	1	pobj	_
4	yes	yes	UH	p2=RB	14	intj	14:AM-DIS
5	,	,	,	_	14	punct	_
6	in	in	IN	_	14	prep	14:AM-LOC
7	a	a	DT	_	9	det	_
8	way	way	NN	_	9	nn	_
9	no.	no.	NN	_	6	pobj	_
10	Under	under	IN	_	9	prep	_
11	the	the	DT	_	13	det	_
12	Takeover	takeover	NNP	p2=NN	13	nn	_
13	Panel	panel	NNP	_	10	pobj	_
14	rules	rule	VBZ	pb=rule.03	0	root	_
15	the	the	DT	_	16	det	_
16	guarantee	guarantee	NN	_	19	nsubj	19:A0=PAG
17	is	be	VBZ	_	19	aux	_
18	legally	legally	RB	_	19	advmod	19:AM-MNR
19	binding	bind	VBG	pb=bind.01	14	ccomp	14:A1=PPT
20	for	for	IN	_	19	prep	19:AM-TMP
21	one	#crd#	CD	_	22	num	_
22	year	year	NN	_	20	pobj	_
23	although	although	IN	_	25	mark	_
24	Pfizer	pfizer	NNP	_	25	nsubj	25:A0=PAG
25	insists	insist	VBZ	pb=insist.01	19	advcl	19:AM-ADV
26	it	it	PRP	_	28	nsubj	28:A0
27	will	will	MD	_	28	aux	28:AM-MOD
28	honour	honour	VB	pb=honor.01	25	ccomp	25:A1=PPT
29	its	its	PRP$	_	30	poss	_
30	pledges	pledge	NNS	_	28	dobj	28:A1
31	for	for	IN	_	28	prep	28:AM-TMP
32	five	#crd#	CD	_	33	num	_
33	years	year	NNS	_	31	pobj	_
34	.	.	.	_	14	punct	_

1	However	however	RB	_	6	advmod	6:AM-DIS
2	,	,	,	_	6	punct	_
3	crucially	crucially	RB	_	6	advmod	6:AM-DIS
4	,	,	,	_	6	punct	_
5	there	there	EX	_	6	expl	_
6	is	be	VBZ	pb=be.02	0	root	_
7	a	a	DT	_	8	det	_
8	clause	clause	NN	_	6	attr	10:A0;6:A1=PPT
9	that	that	WDT	_	10	nsubj	10:R-A0
10	says	say	VBZ	pb=say.01	8	rcmod	_
11	these	these	DT	_	12	det	_
12	obligations	obligation	NNS	_	15	nsubjpass	15:A1=PPT
13	could	could	MD	_	15	aux	15:AM-MOD
14	be	be	VB	_	15	auxpass	_
15	changed	change	VBN	pb=change.01	10	ccomp	10:A1=PPT
16	"	"	``	p2=''	15	punct	_
17	should	should	MD	_	20	aux	20:AM-MOD
18	circumstances	circumstance	NNS	_	20	nsubj	20:A0=PAG
19	significantly	significantly	RB	_	20	advmod	20:AM-MNR
20	change	change	VB	p2=VBP|pb=change.01	15	advcl	_
21	"	"	``	p2=''	23	punct	_
22	ie	ie	JJ	p2=FW	23	amod	_
23	plenty	plenty	NN	_	20	dobj	20:A1=PPT
24	of	of	IN	_	23	prep	_
25	wriggle	wriggle	NN	p2=JJ	26	nn	_
26	room	room	NN	_	24	pobj	_
27	.	.	.	_	6	punct	_

1	In	in	IN	_	4	prep	4:AM-DIS
2	addition	addition	NN	_	1	pobj	_
3	it	it	PRP	_	4	nsubj	_
4	takes	take	VBZ	pb=take.10	26	ccomp	_
5	10	0	CD	_	6	num	_
6	years	year	NNS	_	4	dobj	4:A1
7	for	for	IN	_	11	mark	_
8	a	a	DT	_	9	det	_
9	drug	drug	NN	_	11	nsubj	11:A1=PPT
10	to	to	TO	_	11	aux	_
11	get	get	VB	pb=get.01	4	advcl	4:A0
12	from	from	IN	_	11	prep	11:A2=DIR
13	the	the	DT	_	14	det	_
14	lab	lab	NN	_	12	pobj	_
15	to	to	IN	_	11	prep	_
16	the	the	DT	_	17	det	_
17	doctor	doctor	NN	_	19	poss	_
18	's	's	POS	_	17	possessive	_
19	surgery	surgery	NN	_	15	pobj	_
20	so	so	RB	p2=IN	26	advmod	_
21	a	a	DT	_	25	det	_
22	five	#crd#	CD	_	24	hmod	_
23	-	-	HYPH	_	24	hyph	_
24	year	year	NN	_	25	nn	_
25	guarantee	guarantee	NN	_	26	nsubj	26:A0=PAG
26	means	mean	VBZ	pb=mean.01	0	root	_
27	little	little	JJ	_	26	dobj	26:A1=PPT
28	to	to	IN	_	26	prep	26:A2
29	Britain	britain	NNP	_	32	poss	_
30	's	's	POS	_	29	possessive	_
31	scientific	scientific	JJ	_	32	amod	_
32	researchers	researcher	NNS	_	28	pobj	_
33	.	.	.	_	26	punct	_

1	Ultimately	ultimately	RB	_	7	advmod	7:AM-ADV
2	no.	no.	NFP	p2=NN	7	punct	_
3	The	the	DT	p2=NNP	5	det	_
4	Enterprise	enterprise	NNP	_	5	nn	_
5	Act	act	NNP	_	7	nsubj	7:A0=PAG
6	only	only	RB	_	7	advmod	7:AM-ADV
7	allows	allow	VBZ	pb=allow.01	0	root	_
8	it	it	PRP	_	10	nsubj	10:A1=PPT
9	to	to	TO	p2=IN	10	aux	_
10	step	step	VB	pb=step.01	7	ccomp	7:A1=PPT
11	in	in	RB	p2=IN	10	advmod	10:C-V
12	under	under	IN	_	10	prep	_
13	the	the	DT	_	16	det	_
14	public	public	JJ	_	15	amod	_
15	interest	interest	NN	_	16	nn	_
16	test	test	NN	_	12	pobj	_
17	ie	ie	FW	p2=PRP	22	nn	_
18	if	if	IN	_	20	mark	_
19	it	it	PRP	_	20	nsubj	20:A0=PAG
20	affects	affect	VBZ	pb=affect.01	10	advcl	10:AM-ADV
21	national	national	JJ	_	22	amod	_
22	security	security	NN	_	20	dobj	20:A1=PPT;29:A1
23	or	or	CC	_	22	cc	_
24	financial	financial	JJ	_	25	amod	_
25	stability	stability	NN	_	22	conj	_
26	-	-	:	p2=,	25	punct	_
27	which	which	WDT	_	29	dobj	29:R-A1
28	it	it	PRP	_	29	nsubj	29:A0
29	doesn't	doesn't	VBD	p2=VBZ|pb=doesn't.01	22	rcmod	_
30	.	.	.	_	7	punct	_

1	Business	business	NNP	p2=NN	2	nn	_
2	Secretary	secretary	NNP	_	4	nn	_
3	Vince	vince	NNP	_	4	nn	_
4	Cable	cable	NNP	_	6	nsubj	6:A0=PAG
5	has	have	VBZ	_	6	aux	_
6	suggested	suggest	VBN	pb=suggest.01	0	root	_
7	the	the	DT	_	8	det	_
8	law	law	NN	_	11	nsubjpass	11:A1=PPT
9	could	could	MD	_	11	aux	11:AM-MOD
10	be	be	VB	_	11	auxpass	_
11	changed	change	VBN	p2=JJ|pb=change.01	6	ccomp	6:A1=PPT
12	to	to	TO	p2=IN	13	aux	_
13	include	include	VB	pb=include.01	11	advcl	11:AM-PRP
14	scientific	scientific	JJ	_	15	amod	_
15	research	research	NN	_	13	dobj	13:A1=PPT
16	and	and	CC	_	15	cc	_
17	development	development	NN	_	15	conj	_
18	as	as	IN	_	15	prep	_
19	public	public	JJ	_	20	amod	_
20	interest	interest	NN	_	18	pobj	_
21	.	.	.	_	6	punct	_

1	In	in	IN	_	7	prep	7:AM-LOC
2	any	any	DT	_	3	det	_
3	event	event	NN	_	1	pobj	_
4	the	the	DT	_	6	det	_
5	final	final	JJ	_	6	amod	_
6	say	say	NN	p2=FW	7	nsubj	7:A1=PPT
7	goes	go	VBZ	pb=go.10	0	root	_
8	to	to	IN	_	7	prep	7:A2=GOL
9	the	the	DT	_	11	det	_
10	European	european	NNP	_	11	nn	_
11	Commission	commission	NNP	_	8	pobj	_
12	and	and	CC	_	7	cc	_
13	it	it	PRP	_	15	nsubj	15:A0=PAG
14	will	will	MD	_	15	aux	15:AM-MOD
15	make	make	VB	pb=make.01	7	conj	_
16	the	the	DT	_	17	det	_
17	decision	decision	NN	_	15	dobj	18:A1=PPT;15:AM-PRR
18	based	base	VBN	pb=base.02	17	partmod	_
19	on	on	IN	_	18	prep	18:A2=DIR
20	competition	competition	NN	_	19	pobj	_
21	.	.	.	_	15	punct	_

1	Do	do	VB	_	3	aux	_
2	n't	not	RB	_	3	neg	3:AM-NEG
3	forget	forget	VB	pb=forget.01	0	root	_
4	while	while	IN	_	6	mark	_
5	Pfizer	pfizer	NNP	_	6	nsubj	6:A1=PPT;12:A1=PPT
6	is	be	VBZ	pb=be.01	3	advcl	3:AM-TMP
7	bigger	big	JJR	_	6	acomp	6:A2=PRD
8	than	than	IN	_	7	prep	_
9	AstraZeneca	astrazeneca	NNP	_	8	pobj	_
10	,	,	,	_	12	punct	_
11	neither	neither	CC	p2=DT	12	advmod	12:R-AM-CAU
12	are	be	VBP	pb=be.01	6	conj	_
13	small	small	JJ	_	14	amod	_
14	concerns	concern	NNS	_	12	attr	12:A2=PRD
15	.	.	.	_	3	punct	_

1	A	a	DT	_	2	det	_
2	merger	merger	NN	_	4	nsubj	4:A0=PAG
3	will	will	MD	_	4	aux	4:AM-MOD
4	create	create	VB	pb=create.01	0	root	_
5	a	a	DT	_	7	det	_
6	huge	huge	JJ	_	7	amod	_
7	firm	firm	NN	_	4	dobj	4:A1=PPT
8	.	.	.	_	4	punct	_

1	It	it	PRP	_	3	nsubj	3:A0=PAG
2	will	will	MD	_	3	aux	3:AM-MOD
3	represent	represent	VB	pb=represent.01	0	root	_
4	the	the	DT	_	7	det	_
5	biggest	big	JJS	p2=RBS	7	amod	_
6	ever	ever	RB	p2=JJ	7	advmod	_
7	takeover	takeover	NN	_	3	dobj	3:A1=PPT
8	of	of	IN	_	7	prep	_
9	a	a	DT	_	11	det	_
10	British	british	JJ	_	11	amod	_
11	firm	firm	NN	_	8	pobj	_
12	by	by	IN	_	7	prep	_
13	a	a	DT	_	15	det	_
14	foreign	foreign	JJ	_	15	amod	_
15	company	company	NN	_	12	pobj	_
16	.	.	.	_	3	punct	_

1	There	there	EX	_	2	expl	_
2	are	be	VBP	pb=be.02	0	root	_
3	very	very	RB	p2=JJ	4	advmod	_
4	real	real	JJ	_	5	amod	_
5	concerns	concern	NNS	_	2	attr	2:A1=PPT
6	such	such	JJ	p2=RB	10	amod	_
7	big	big	JJ	p2=NN	10	amod	_
8	"	"	``	_	10	punct	_
9	big	big	JJ	_	10	amod	_
10	pharma	pharma	NN	_	14	nsubj	14:A0=PAG
11	"	"	''	_	14	punct	_
12	will	will	MD	_	14	aux	14:AM-MOD
13	completely	completely	RB	_	14	advmod	14:AM-EXT
14	ruin	ruin	VB	pb=ruin.01	5	ccomp	_
15	small	small	JJ	_	16	amod	_
16	science	science	NN	_	17	nn	_
17	research	research	NN	_	18	nn	_
18	outfits	outfits	NN	p2=NNS	14	dobj	14:A1=PPT
19	.	.	.	_	2	punct	_

1	Remember	remember	VB	pb=remember.01	13	advcl	_
2	AstraZeneca	astrazeneca	NNP	_	5	nsubj	5:A0=PAG
3	and	and	CC	_	2	cc	_
4	Pfizer	pfizer	NNP	_	2	conj	_
5	have	have	VBP	p2=VB|pb=have.03	1	ccomp	1:A1=PPT
6	sites	site	NNS	_	5	dobj	5:A1=PPT
7	all	all	RB	_	8	advmod	_
8	over	over	IN	p2=RB	6	prep	_
9	this	this	DT	_	10	det	_
10	world	world	NN	_	8	pobj	_
11	,	,	,	_	13	punct	_
12	this	this	DT	_	13	nsubj	13:A1=PPT
13	is	be	VBZ	pb=be.01	0	root	_
14	not	not	RB	_	13	neg	13:AM-NEG
15	just	just	RB	_	16	advmod	_
16	about	about	IN	_	13	prep	13:A2=PRD
17	the	the	DT	_	18	det	_
18	UK	uk	NNP	_	16	pobj	_
19	and	and	CC	_	18	cc	_
20	US	us	NNP	_	21	nn	_
21	politicians	politician	NNS	_	18	conj	_
22	have	have	VBP	_	24	aux	_
23	also	also	RB	_	24	advmod	24:AM-ADV
24	raised	raise	VBN	pb=raise.01	13	conj	_
25	concerns	concern	NNS	_	24	dobj	24:A1=PPT
26	over	over	IN	_	25	prep	_
27	jobs	job	NNS	_	26	pobj	_
28	.	.	.	_	13	punct	_

1	Well	well	UH	_	5	intj	5:AM-DIS
2	Pfizer	pfizer	NNP	p2=NN	5	nsubj	5:A0=PAG;11:A0=PAG
3	will	will	MD	_	5	aux	5:AM-MOD
4	be	be	VB	_	5	aux	_
5	paying	pay	VBG	pb=pay.01	0	root	_
6	tax	tax	NN	_	5	dobj	5:A1=VSP
7	to	to	IN	_	5	prep	5:A2=GOL
8	the	the	DT	_	9	det	_
9	Government	government	NNP	p2=NN	7	pobj	_
10	and	and	CC	_	5	cc	_
11	investing	invest	VBG	p2=NN|pb=invest.01	5	conj	_
12	in	in	IN	_	11	prep	11:A2=GOL
13	Britain	britain	NNP	_	12	pobj	_
14	-	-	,	p2=HYPH	5	punct	_
15	all	all	DT	p2=RB	16	advmod	_
16	good	good	JJ	p2=NN	5	dobj	_
17	.	.	.	_	5	punct	_

1	And	and	CC	_	3	cc	3:AM-DIS
2	it	it	PRP	_	3	nsubj	3:A0
3	says	say	VBZ	pb=say.01	0	root	_
4	that	that	IN	_	12	complm	_
5	the	the	DT	_	7	det	_
6	combined	combined	JJ	p2=VBN	7	amod	_
7	power	power	NN	_	12	nsubj	12:A0=PAG
8	of	of	IN	_	7	prep	_
9	both	both	DT	_	10	det	_
10	companies	company	NNS	_	8	pobj	_
11	will	will	MD	_	12	aux	12:AM-MOD
12	bring	bring	VB	pb=bring.01	3	ccomp	3:A1=PPT
13	improved	improved	JJ	p2=VBN	14	amod	_
14	treatments	treatment	NNS	_	12	dobj	12:A1=PPT
15	for	for	IN	_	12	prep	12:AM-PRP
16	conditions	condition	NNS	_	15	pobj	_
17	such	such	JJ	_	18	amod	_
18	as	as	IN	_	16	prep	_
19	cancer	cancer	NN	_	18	pobj	_
20	,	,	,	_	19	punct	_
21	heart	heart	NN	_	22	nn	_
22	disease	disease	NN	_	19	conj	_
23	and	and	CC	_	22	cc	_
24	diabetes	diabetes	NN	_	22	conj	_
25	.	.	.	_	3	punct	_

1	In	in	IN	_	5	prep	5:AM-DIS
2	addition	addition	NN	_	1	pobj	_
3	,	,	,	_	5	punct	_
4	it	it	PRP	_	5	nsubj	5:A1=PPT
5	is	be	VBZ	pb=be.01	0	root	_
6	investment	investment	NN	_	5	attr	5:A2=PRD
7	in	in	IN	_	6	prep	_
8	science	science	NN	_	7	pobj	11:A1=PPT
9	,	,	,	_	8	punct	_
10	which	which	WDT	_	11	nsubj	11:R-A1
11	is	be	VBZ	pb=be.01	8	rcmod	_
12	key	key	JJ	p2=NN	11	acomp	11:A2=PRD
13	to	to	IN	_	12	prep	_
14	the	the	DT	_	15	det	_
15	Government	government	NNP	p2=NN	18	poss	_
16	's	's	POS	_	15	possessive	_
17	economic	economic	JJ	_	18	amod	_
18	strategy	strategy	NN	_	13	pobj	_
19	.	.	.	_	5	punct	_

1	MPs	mp	NNS	p2=NNP	9	nsubj	9:A0
2	on	on	IN	_	1	prep	_
3	House	house	NNP	_	2	pobj	_
4	of	of	IN	_	3	prep	_
5	Commons	commons	NNP	_	6	nn	_
6	committees	committee	NNS	_	4	pobj	_
7	have	have	VBP	_	9	aux	_
8	been	be	VBN	_	9	aux	_
9	hearing	hear	VBG	pb=hear.01	0	root	_
10	from	from	IN	_	9	prep	9:A2=DIR
11	the	the	DT	_	12	det	_
12	firms	firm	NNS	_	10	pobj	_
13	and	and	CC	_	10	cc	_
14	from	from	IN	_	10	conj	_
15	unions	union	NNS	_	14	pobj	16:A0=PPT
16	worried	worry	VBN	p2=JJ|pb=worry.02	15	partmod	_
17	about	about	IN	_	16	prep	16:A1=PAG
18	job	job	NN	_	19	nn	_
19	cuts	cut	NNS	_	17	pobj	_
20	but	but	CC	_	16	cc	_
21	ultimately	ultimately	RB	_	25	advmod	25:AM-TMP
22	that	that	DT	p2=WDT	25	nsubj	25:A0=PAG
23	is	be	VBZ	_	25	aux	_
24	just	just	RB	p2=JJ	25	advmod	25:AM-ADV
25	talk	talk	VB	p2=NN|pb=talk.01	16	conj	_
26	.	.	.	_	9	punct	_

1	Under	under	IN	_	14	prep	14:AM-LOC
2	Takeover	takeover	NNP	p2=NN	3	nn	_
3	Panel	panel	NNP	_	4	nn	_
4	rules	rule	NNS	p2=VBZ	1	pobj	6:A0=CAU
5	having	have	VBG	_	6	aux	_
6	indicated	indicate	VBN	p2=VBD|pb=indicate.01	4	partmod	_
7	its	its	PRP$	_	8	poss	_
8	interest	interest	NN	_	6	dobj	6:A1=PPT
9	on	on	IN	_	6	prep	6:AM-TMP
10	April	april	NNP	_	9	pobj	_
11	26	0	CD	_	10	num	_
12	,	,	,	_	14	punct	_
13	Pfizer	pfizer	NNP	_	14	nsubj	14:A0=PAG
14	has	have	VBZ	pb=have.03	0	root	_
15	until	until	IN	_	14	prep	14:AM-TMP
16	May	may	NNP	_	15	pobj	_
17	26	0	CD	_	16	num	_
18	to	to	TO	_	19	aux	_
19	make	make	VB	pb=make.02	14	xcomp	_
20	an	an	DT	_	22	det	_
21	official	official	JJ	p2=NN	22	amod	_
22	bid	bid	NN	_	19	dobj	19:AM-PRR
23	.	.	.	_	14	punct	_

1	AstraZeneca	astrazeneca	NNP	_	4	poss	_
2	's	's	POS	_	1	possessive	_
3	chief	chief	JJ	_	4	amod	_
4	executive	executive	NN	_	8	nsubj	8:A0=PAG
5	,	,	,	_	4	punct	_
6	Pascal	pascal	NNP	_	7	nn	_
7	Soriot	soriot	NNP	_	4	appos	_
8	speaks	speak	VBZ	pb=speak.01	0	root	_
9	to	to	IN	_	8	prep	8:A2=GOL
10	Sky	sky	NNP	_	13	poss	_
11	's	's	POS	_	10	possessive	_
12	Ian	ian	NNP	_	13	nn	_
13	King	king	NNP	_	9	pobj	_
14	about	about	IN	_	8	prep	8:A1=PPT
15	Pfizer	pfizer	NNP	_	18	poss	_
16	's	's	POS	_	15	possessive	_
17	takeover	takeover	NN	_	18	nn	_
18	bid	bid	NN	_	14	pobj	_
19	.	.	.	_	8	punct	_

1	Video	video	NNP	p2=NN	4	dep	_
2	:	:	:	_	4	punct	_
3	AstraZeneca	astrazeneca	NNP	p2=JJ	4	nn	_
4	chairman	chairman	NN	_	0	root	_
5	:	:	:	_	4	punct	_
6	'	'	''	p2=``	4	punct	_
7	Bid	bid	NNP	p2=JJ	8	nsubj	8:A0=PAG
8	creates	create	VBZ	pb=create.01	4	appos	_
9	considerable	considerable	JJ	_	10	amod	_
10	risk	risk	NN	_	8	dobj	8:A1=PPT
11	'	'	''	p2=POS	4	punct	_

